Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

GAIL J ROBOZ

Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology

NPI
1417044504
CMS profile
18881
Location
NEW YORK, NY

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$96,257.99

75 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2023 · entire year · sorted by reported total

By paying entity

PY2023 · entire year · sorted by reported total

Paying entityAmountRecords
AbbVie Inc. $39,889.38 48
GlaxoSmithKline, LLC. $15,000.00 4
Celgene Corporation $14,334.40 4
Daiichi Sankyo Inc. $9,466.21 5
Genentech, Inc. $7,462.87 4
Gilead Sciences, Inc. $3,926.23 4
Rigel Pharmaceuticals, Inc. $3,750.00 2
Telix Pharmaceuticals $1,500.00 1
Amgen Inc. $750.00 1
Astellas Pharma US Inc $178.90 2

Page 2 of 2; records 51–75 of 75 matching records. This page contains 25 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

GAIL J ROBOZ

NPI 1417044504 · CMS profile ID 18881

Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology

NEW YORK, NY

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 2; records 51–75 of 75 matching records. This page contains 25 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1417044504?year=2023&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
GAIL J ROBOZ, NPI 1417044504, CMS profile ID 18881. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–75 of 75 matching records. This page contains 25 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1417044504?year=2023&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). GAIL J ROBOZ, NPI 1417044504, CMS profile ID 18881. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–75 of 75 matching records. This page contains 25 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1417044504?year=2023&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
GAIL J ROBOZ, NPI 1417044504, CMS profile ID 18881, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–75 of 75 matching records. This page contains 25 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1417044504?year=2023&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

75 matching records · $96,257.99 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 75 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–75 of 75.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
AbbVie Inc. $44.5304/28/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998649515 CMS
AbbVie Inc. $11.1304/28/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998649521 CMS
AbbVie Inc. $11.1304/28/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998649527 CMS
AbbVie Inc. $84.5304/28/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998649531 CMS
AbbVie Inc. $275.7904/27/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998649491 CMS
AbbVie Inc. $237.0204/27/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998649497 CMS
AbbVie Inc. $66.8004/27/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998649503 CMS
AbbVie Inc. $237.0204/26/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998649485 CMS
Rigel Pharmaceuticals, Inc. $2,250.0004/26/2023 Honoraria No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1033404605 CMS
Amgen Inc. $750.0004/24/2023 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1019912791 CMS
Daiichi Sankyo Inc. $11.4103/22/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1006531913 CMS
Daiichi Sankyo Inc. $342.3003/22/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1006531921 CMS
Daiichi Sankyo Inc. $3,112.5003/22/2023 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1006532135 CMS
AbbVie Inc. $10.6303/19/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998649475 CMS
AbbVie Inc. $10.6303/19/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998649481 CMS
AbbVie Inc. $198.8203/18/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998649453 CMS
AbbVie Inc. $179.7703/18/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998649459 CMS
AbbVie Inc. $5.3103/18/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998649465 CMS
AbbVie Inc. $5.3103/18/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998649471 CMS
AbbVie Inc. $179.7703/17/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998649443 CMS
AbbVie Inc. $6,827.1103/17/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998649447 CMS
AbbVie Inc. $15.8801/11/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998649425 CMS
AbbVie Inc. $10.5101/11/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998649431 CMS
AbbVie Inc. $2,625.0001/11/2023 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998649436 CMS
GlaxoSmithKline, LLC. $7,500.0001/10/2023 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1001807247 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $164,580.93 120
PY2020 $115,658.80 37
PY2021 $103,584.30 23
PY2022 $111,105.79 46
PY2023 $96,257.99 75
PY2024 $81,548.57 35
PY2025 $65,538.93 41

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $1,187,122.57 309
PY2024 Principal investigator $824,289.53 39
PY2023 Recipient $5,173.52 4
PY2023 Principal investigator $643,301.27 39
PY2022 Recipient $1,800.00 1
PY2022 Principal investigator $1,029,648.96 46
PY2021 Recipient $25,020.00 4
PY2021 Principal investigator $815,581.90 35
PY2020 Recipient $61,454.17 9
PY2020 Principal investigator $1,193,676.07 42
PY2019 Recipient $31,209.10 6
PY2019 Principal investigator $1,651,544.72 85

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

309 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $300.00 12/31/2025 Non-covered Recipient Entity
CORNELL UNIVERSITY WEILL MED COLLEGE
A Phase 1 first-in-human study evaluating safety, pharmacokinetics and efficacy of ABBV-787 in adult subjects with acute myeloid leukemia (AML) No dispute reported 06/30/2026 1202533631
Principal investigator 1 Astellas Pharma Global Development $886.00 12/24/2025 Non-covered Recipient Entity
WEILL MEDICAL COLLEGE OF CORNELL UNIVERSITY
A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy No dispute reported 06/30/2026 1234188165
Principal investigator 1 Astellas Pharma Global Development $500.00 12/24/2025 Non-covered Recipient Entity
WEILL MEDICAL COLLEGE OF CORNELL UNIVERSITY
A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy No dispute reported 06/30/2026 1234188167
Principal investigator 1 TAIHO ONCOLOGY, INC. $45,774.76 12/19/2025 Non-covered Recipient Entity
Weill Medical College Of Cornell University
Pharmacokinetics, Safety, and Efficacy of ASTX727 in Combination With Venetoclax in Acute Myeloid Leukemia (AML) No dispute reported 06/30/2026 1211418333
Principal investigator 1 TAIHO ONCOLOGY, INC. $1,500.00 12/01/2025 Non-covered Recipient Entity
Weill Medical College Of Cornell University
Pharmacokinetics, Safety, and Efficacy of ASTX727 in Combination With Venetoclax in Acute Myeloid Leukemia (AML) No dispute reported 06/30/2026 1211417609
Principal investigator 1 ABBVIE INC. $12,833.11 10/30/2025 Non-covered Recipient Entity
CORNELL UNIVERSITY WEILL MEDICAL COLLEGE
Study Of Venetoclax Tablet With Intravenous or Subcutaneous Azacitidine to Assess Change in Disease Activity In Adult Participants With Newly Diagnosed Higher-Risk Myelodysplastic Syndrome No dispute reported 06/30/2026 1202519871
Principal investigator 1 Astellas Pharma Global Development $540.00 10/29/2025 Non-covered Recipient Entity
WEILL MEDICAL COLLEGE OF CORNELL UNIVERSITY
A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy No dispute reported 06/30/2026 1234188109
Principal investigator 1 Astellas Pharma Global Development $109.00 10/29/2025 Non-covered Recipient Entity
WEILL MEDICAL COLLEGE OF CORNELL UNIVERSITY
A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy No dispute reported 06/30/2026 1234188135
Principal investigator 1 ABBVIE INC. $8,344.32 10/22/2025 Non-covered Recipient Entity
CORNELL UNIVERSITY WEILL MEDICAL COLLEGE
A Study Evaluating Venetoclax in Combination With Azacitidine in Participants With Treatment- Higher-Risk Myelodysplastic Syndromes (MDS) No dispute reported 06/30/2026 1202518165
Principal investigator 1 Astellas Pharma Global Development $1,182.94 10/22/2025 Non-covered Recipient Entity
WEILL MEDICAL COLLEGE OF CORNELL UNIVERSITY
A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy No dispute reported 06/30/2026 1234188111
Principal investigator 1 Astellas Pharma Global Development $1,281.80 10/22/2025 Non-covered Recipient Entity
WEILL MEDICAL COLLEGE OF CORNELL UNIVERSITY
A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy No dispute reported 06/30/2026 1234188113
Principal investigator 1 Astellas Pharma Global Development $3,465.00 10/22/2025 Non-covered Recipient Entity
WEILL MEDICAL COLLEGE OF CORNELL UNIVERSITY
A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy No dispute reported 06/30/2026 1234188115
Principal investigator 1 Astellas Pharma Global Development $1,281.80 10/22/2025 Non-covered Recipient Entity
WEILL MEDICAL COLLEGE OF CORNELL UNIVERSITY
A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy No dispute reported 06/30/2026 1234188117
Principal investigator 1 Astellas Pharma Global Development $3,689.90 10/22/2025 Non-covered Recipient Entity
WEILL MEDICAL COLLEGE OF CORNELL UNIVERSITY
A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy No dispute reported 06/30/2026 1234188119
Principal investigator 1 Astellas Pharma Global Development $1,783.69 10/22/2025 Non-covered Recipient Entity
WEILL MEDICAL COLLEGE OF CORNELL UNIVERSITY
A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy No dispute reported 06/30/2026 1234188121
Principal investigator 1 Astellas Pharma Global Development $1,281.80 10/22/2025 Non-covered Recipient Entity
WEILL MEDICAL COLLEGE OF CORNELL UNIVERSITY
A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy No dispute reported 06/30/2026 1234188123
Principal investigator 1 Astellas Pharma Global Development $5,245.09 10/22/2025 Non-covered Recipient Entity
WEILL MEDICAL COLLEGE OF CORNELL UNIVERSITY
A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy No dispute reported 06/30/2026 1234188125
Principal investigator 1 Astellas Pharma Global Development $1,281.80 10/22/2025 Non-covered Recipient Entity
WEILL MEDICAL COLLEGE OF CORNELL UNIVERSITY
A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy No dispute reported 06/30/2026 1234188127
Principal investigator 1 Astellas Pharma Global Development $4,299.41 10/22/2025 Non-covered Recipient Entity
WEILL MEDICAL COLLEGE OF CORNELL UNIVERSITY
A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy No dispute reported 06/30/2026 1234188129
Principal investigator 1 Astellas Pharma Global Development $3,724.99 10/22/2025 Non-covered Recipient Entity
WEILL MEDICAL COLLEGE OF CORNELL UNIVERSITY
A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy No dispute reported 06/30/2026 1234188131
Principal investigator 1 Astellas Pharma Global Development $1,281.80 10/22/2025 Non-covered Recipient Entity
WEILL MEDICAL COLLEGE OF CORNELL UNIVERSITY
A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy No dispute reported 06/30/2026 1234188133
Principal investigator 1 Astellas Pharma Global Development $5,245.09 10/22/2025 Non-covered Recipient Entity
WEILL MEDICAL COLLEGE OF CORNELL UNIVERSITY
A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy No dispute reported 06/30/2026 1234188137
Principal investigator 1 Astellas Pharma Global Development $1,932.19 10/22/2025 Non-covered Recipient Entity
WEILL MEDICAL COLLEGE OF CORNELL UNIVERSITY
A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy No dispute reported 06/30/2026 1234188139
Principal investigator 1 Astellas Pharma Global Development $3,689.90 10/22/2025 Non-covered Recipient Entity
WEILL MEDICAL COLLEGE OF CORNELL UNIVERSITY
A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy No dispute reported 06/30/2026 1234188143
Principal investigator 1 Astellas Pharma Global Development $1,281.80 10/22/2025 Non-covered Recipient Entity
WEILL MEDICAL COLLEGE OF CORNELL UNIVERSITY
A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy No dispute reported 06/30/2026 1234188145
Principal investigator 1 Astellas Pharma Global Development $1,972.69 10/22/2025 Non-covered Recipient Entity
WEILL MEDICAL COLLEGE OF CORNELL UNIVERSITY
A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy No dispute reported 06/30/2026 1234188147
Principal investigator 1 Astellas Pharma Global Development $1,281.80 10/22/2025 Non-covered Recipient Entity
WEILL MEDICAL COLLEGE OF CORNELL UNIVERSITY
A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy No dispute reported 06/30/2026 1234188149
Principal investigator 1 Astellas Pharma Global Development $1,281.80 10/22/2025 Non-covered Recipient Entity
WEILL MEDICAL COLLEGE OF CORNELL UNIVERSITY
A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy No dispute reported 06/30/2026 1234188151
Principal investigator 1 Astellas Pharma Global Development $1,281.80 10/22/2025 Non-covered Recipient Entity
WEILL MEDICAL COLLEGE OF CORNELL UNIVERSITY
A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy No dispute reported 06/30/2026 1234188153
Principal investigator 1 Astellas Pharma Global Development $3,724.99 10/22/2025 Non-covered Recipient Entity
WEILL MEDICAL COLLEGE OF CORNELL UNIVERSITY
A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy No dispute reported 06/30/2026 1234188155
Principal investigator 1 Astellas Pharma Global Development $1,281.80 10/22/2025 Non-covered Recipient Entity
WEILL MEDICAL COLLEGE OF CORNELL UNIVERSITY
A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy No dispute reported 06/30/2026 1234188157
Principal investigator 1 Astellas Pharma Global Development $1,281.80 10/22/2025 Non-covered Recipient Entity
WEILL MEDICAL COLLEGE OF CORNELL UNIVERSITY
A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy No dispute reported 06/30/2026 1234188159
Principal investigator 1 Astellas Pharma Global Development $1,281.80 10/22/2025 Non-covered Recipient Entity
WEILL MEDICAL COLLEGE OF CORNELL UNIVERSITY
A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy No dispute reported 06/30/2026 1234188161
Principal investigator 1 Astellas Pharma Global Development $1,701.00 10/13/2025 Non-covered Recipient Entity
WEILL MEDICAL COLLEGE OF CORNELL UNIVERSITY
A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy No dispute reported 06/30/2026 1234188141
Principal investigator 1 Astellas Pharma Global Development $500.00 10/13/2025 Non-covered Recipient Entity
WEILL MEDICAL COLLEGE OF CORNELL UNIVERSITY
A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy No dispute reported 06/30/2026 1234188163
Principal investigator 1 TAIHO ONCOLOGY, INC. $5,242.42 10/13/2025 Non-covered Recipient Entity
Weill Medical College Of Cornell University
Pharmacokinetics, Safety, and Efficacy of ASTX727 in Combination With Venetoclax in Acute Myeloid Leukemia (AML) No dispute reported 06/30/2026 1211420475
Principal investigator 1 ABBVIE INC. $33,120.00 09/18/2025 Non-covered Recipient Entity
CORNELL UNIVERSITY WEILL MEDICAL COLLEGE
Study Of Venetoclax Tablet With Intravenous or Subcutaneous Azacitidine to Assess Change in Disease Activity In Adult Participants With Newly Diagnosed Higher-Risk Myelodysplastic Syndrome No dispute reported 06/30/2026 1202511388
Principal investigator 1 TAIHO ONCOLOGY, INC. $5,242.42 09/15/2025 Non-covered Recipient Entity
Weill Medical College Of Cornell University
ASTX727-07 No dispute reported 06/30/2026 1211415507
Principal investigator 1 Astellas Pharma Global Development $4,000.00 09/03/2025 Non-covered Recipient Entity
WEILL MEDICAL COLLEGE OF CORNELL UNIVERSITY
A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy No dispute reported 06/30/2026 1234188105
Principal investigator 1 Astellas Pharma Global Development $13,000.00 09/03/2025 Non-covered Recipient Entity
WEILL MEDICAL COLLEGE OF CORNELL UNIVERSITY
A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy No dispute reported 06/30/2026 1234188107
Principal investigator 1 TAIHO ONCOLOGY, INC. $15,750.00 09/03/2025 Non-covered Recipient Entity
Weill Medical College Of Cornell University
ASTX727-07 No dispute reported 06/30/2026 1211417611
Principal investigator 1 Janssen Research & Development, LLC $250,000.00 08/29/2025 Non-covered Recipient Entity
WEILL CORNELL MEDICAL COLLEGE
The premalignant mutational landscape of non-myeloid hematological malignancies and secondary acute myeloid leukemia No dispute reported 06/30/2026 1175308233
Principal investigator 1 Celgene Corporation $18,646.50 08/20/2025 Non-covered Recipient Entity
Weill Medical College Of Cornell University
Connect Myeloid: The Myelofibrosis (MF), Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry. The purpose of the Connect Myeloid disease registry is to provide unique insights into treatment decisions and treatment patterns as they relate to clinical outcomes of patients with myeloid diseases in routine clinical practice. No dispute reported 06/30/2026 1222304931
Principal investigator 1 TAIHO ONCOLOGY, INC. $16,045.29 08/14/2025 Non-covered Recipient Entity
Weill Medical College Of Cornell University
ASTX727-07 No dispute reported 06/30/2026 1211420477
Principal investigator 1 TAIHO ONCOLOGY, INC. $137,417.30 08/07/2025 Non-covered Recipient Entity
Weill Medical College Of Cornell University
ASTX727-07 No dispute reported 06/30/2026 1211417613
Principal investigator 1 ABBVIE INC. $62.00 07/18/2025 Non-covered Recipient Entity
WEILL MEDICAL COLLEGE OF CORNELL UNIVERSITY
Study to Evaluate Adverse Events and Movement of Intravenously (IV) Infused ABBV-787 in Adult Participants With Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) No dispute reported 06/30/2026 1202498840
Principal investigator 1 ABBVIE INC. $62.00 07/18/2025 Non-covered Recipient Entity
WEILL MEDICAL COLLEGE OF CORNELL UNIVERSITY
Study to Evaluate Adverse Events and Movement of Intravenously (IV) Infused ABBV-787 in Adult Participants With Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) No dispute reported 06/30/2026 1202498852
Principal investigator 1 ABBVIE INC. $3,500.00 07/18/2025 Non-covered Recipient Entity
WEILL MEDICAL COLLEGE OF CORNELL UNIVERSITY
Study to Evaluate Adverse Events and Movement of Intravenously (IV) Infused ABBV-787 in Adult Participants With Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) No dispute reported 06/30/2026 1202498890
Principal investigator 1 ABBVIE INC. $50.00 07/18/2025 Non-covered Recipient Entity
WEILL MEDICAL COLLEGE OF CORNELL UNIVERSITY
Study to Evaluate Adverse Events and Movement of Intravenously (IV) Infused ABBV-787 in Adult Participants With Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) No dispute reported 06/30/2026 1202498892
Principal investigator 1 ABBVIE INC. $195.75 07/18/2025 Non-covered Recipient Entity
WEILL MEDICAL COLLEGE OF CORNELL UNIVERSITY
Study to Evaluate Adverse Events and Movement of Intravenously (IV) Infused ABBV-787 in Adult Participants With Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) No dispute reported 06/30/2026 1202498894
Principal investigator 1 ABBVIE INC. $3,500.00 07/18/2025 Non-covered Recipient Entity
WEILL MEDICAL COLLEGE OF CORNELL UNIVERSITY
Study to Evaluate Adverse Events and Movement of Intravenously (IV) Infused ABBV-787 in Adult Participants With Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) No dispute reported 06/30/2026 1202498896
Principal investigator 1 ABBVIE INC. $236.25 07/18/2025 Non-covered Recipient Entity
WEILL MEDICAL COLLEGE OF CORNELL UNIVERSITY
Study to Evaluate Adverse Events and Movement of Intravenously (IV) Infused ABBV-787 in Adult Participants With Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) No dispute reported 06/30/2026 1202498898
Principal investigator 1 ABBVIE INC. $130.95 07/18/2025 Non-covered Recipient Entity
WEILL MEDICAL COLLEGE OF CORNELL UNIVERSITY
Study to Evaluate Adverse Events and Movement of Intravenously (IV) Infused ABBV-787 in Adult Participants With Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) No dispute reported 06/30/2026 1202498900
Principal investigator 1 ABBVIE INC. $1,113.75 06/26/2025 Non-covered Recipient Entity
WEILL MEDICAL COLLEGE OF CORNELL UNIVERSITY
Study to Evaluate Adverse Events and Movement of Intravenously (IV) Infused ABBV-787 in Adult Participants With Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) No dispute reported 06/30/2026 1202492985
Principal investigator 1 ABBVIE INC. $1,113.75 06/26/2025 Non-covered Recipient Entity
WEILL MEDICAL COLLEGE OF CORNELL UNIVERSITY
Study to Evaluate Adverse Events and Movement of Intravenously (IV) Infused ABBV-787 in Adult Participants With Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) No dispute reported 06/30/2026 1202492993
Principal investigator 1 ABBVIE INC. $1,113.75 06/26/2025 Non-covered Recipient Entity
WEILL MEDICAL COLLEGE OF CORNELL UNIVERSITY
Study to Evaluate Adverse Events and Movement of Intravenously (IV) Infused ABBV-787 in Adult Participants With Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) No dispute reported 06/30/2026 1202493029
Principal investigator 1 Karyopharm Therapeutics Inc. $170.00 06/13/2025 Non-covered Recipient Entity
Weill Cornell Medical College
A Phase 1/2 Open-Label Study of the Safety, Tolerability and Efficacy of the Selective Inhibitor of Nuclear Export (SINE) Compound KPT-8602 in Patients with Relapsed, Refractory Cancer Indications No dispute reported 06/30/2026 1246667311
Principal investigator 1 Karyopharm Therapeutics Inc. $170.00 06/13/2025 Non-covered Recipient Entity
Weill Cornell Medical College
A Phase 1/2 Open-Label Study of the Safety, Tolerability and Efficacy of the Selective Inhibitor of Nuclear Export (SINE) Compound KPT-8602 in Patients with Relapsed, Refractory Cancer Indications No dispute reported 06/30/2026 1246667313
Principal investigator 1 Karyopharm Therapeutics Inc. $311.00 06/13/2025 Non-covered Recipient Entity
Weill Cornell Medical College
A Phase 1/2 Open-Label Study of the Safety, Tolerability and Efficacy of the Selective Inhibitor of Nuclear Export (SINE) Compound KPT-8602 in Patients with Relapsed, Refractory Cancer Indications No dispute reported 06/30/2026 1246667315
Principal investigator 1 Karyopharm Therapeutics Inc. $170.00 06/13/2025 Non-covered Recipient Entity
Weill Cornell Medical College
A Phase 1/2 Open-Label Study of the Safety, Tolerability and Efficacy of the Selective Inhibitor of Nuclear Export (SINE) Compound KPT-8602 in Patients with Relapsed, Refractory Cancer Indications No dispute reported 06/30/2026 1246667317
Principal investigator 1 Karyopharm Therapeutics Inc. $170.00 06/13/2025 Non-covered Recipient Entity
Weill Cornell Medical College
A Phase 1/2 Open-Label Study of the Safety, Tolerability and Efficacy of the Selective Inhibitor of Nuclear Export (SINE) Compound KPT-8602 in Patients with Relapsed, Refractory Cancer Indications No dispute reported 06/30/2026 1246667319
Principal investigator 1 Karyopharm Therapeutics Inc. $928.80 06/13/2025 Non-covered Recipient Entity
Weill Cornell Medical College
A Phase 1/2 Open-Label Study of the Safety, Tolerability and Efficacy of the Selective Inhibitor of Nuclear Export (SINE) Compound KPT-8602 in Patients with Relapsed, Refractory Cancer Indications No dispute reported 06/30/2026 1246667321
Principal investigator 1 Karyopharm Therapeutics Inc. $1,750.00 06/13/2025 Non-covered Recipient Entity
Weill Cornell Medical College
A Phase 1/2 Open-Label Study of the Safety, Tolerability and Efficacy of the Selective Inhibitor of Nuclear Export (SINE) Compound KPT-8602 in Patients with Relapsed, Refractory Cancer Indications No dispute reported 06/30/2026 1246667323
Principal investigator 1 Karyopharm Therapeutics Inc. $170.00 06/13/2025 Non-covered Recipient Entity
Weill Cornell Medical College
A Phase 1/2 Open-Label Study of the Safety, Tolerability and Efficacy of the Selective Inhibitor of Nuclear Export (SINE) Compound KPT-8602 in Patients with Relapsed, Refractory Cancer Indications No dispute reported 06/30/2026 1246667325
Principal investigator 1 Karyopharm Therapeutics Inc. $170.00 06/13/2025 Non-covered Recipient Entity
Weill Cornell Medical College
A Phase 1/2 Open-Label Study of the Safety, Tolerability and Efficacy of the Selective Inhibitor of Nuclear Export (SINE) Compound KPT-8602 in Patients with Relapsed, Refractory Cancer Indications No dispute reported 06/30/2026 1246667327
Principal investigator 1 Karyopharm Therapeutics Inc. $170.00 06/13/2025 Non-covered Recipient Entity
Weill Cornell Medical College
A Phase 1/2 Open-Label Study of the Safety, Tolerability and Efficacy of the Selective Inhibitor of Nuclear Export (SINE) Compound KPT-8602 in Patients with Relapsed, Refractory Cancer Indications No dispute reported 06/30/2026 1246667329
Principal investigator 1 Karyopharm Therapeutics Inc. $170.00 06/13/2025 Non-covered Recipient Entity
Weill Cornell Medical College
A Phase 1/2 Open-Label Study of the Safety, Tolerability and Efficacy of the Selective Inhibitor of Nuclear Export (SINE) Compound KPT-8602 in Patients with Relapsed, Refractory Cancer Indications No dispute reported 06/30/2026 1246667331
Principal investigator 1 Karyopharm Therapeutics Inc. $170.00 06/13/2025 Non-covered Recipient Entity
Weill Cornell Medical College
A Phase 1/2 Open-Label Study of the Safety, Tolerability and Efficacy of the Selective Inhibitor of Nuclear Export (SINE) Compound KPT-8602 in Patients with Relapsed, Refractory Cancer Indications No dispute reported 06/30/2026 1246667333
Principal investigator 1 Karyopharm Therapeutics Inc. $320.00 06/13/2025 Non-covered Recipient Entity
Weill Cornell Medical College
A Phase 1/2 Open-Label Study of the Safety, Tolerability and Efficacy of the Selective Inhibitor of Nuclear Export (SINE) Compound KPT-8602 in Patients with Relapsed, Refractory Cancer Indications No dispute reported 06/30/2026 1246667335
Principal investigator 1 Karyopharm Therapeutics Inc. $320.00 06/13/2025 Non-covered Recipient Entity
Weill Cornell Medical College
A Phase 1/2 Open-Label Study of the Safety, Tolerability and Efficacy of the Selective Inhibitor of Nuclear Export (SINE) Compound KPT-8602 in Patients with Relapsed, Refractory Cancer Indications No dispute reported 06/30/2026 1246667337
Principal investigator 1 Karyopharm Therapeutics Inc. $170.00 06/13/2025 Non-covered Recipient Entity
Weill Cornell Medical College
A Phase 1/2 Open-Label Study of the Safety, Tolerability and Efficacy of the Selective Inhibitor of Nuclear Export (SINE) Compound KPT-8602 in Patients with Relapsed, Refractory Cancer Indications No dispute reported 06/30/2026 1246667339
Principal investigator 1 Karyopharm Therapeutics Inc. $170.00 06/13/2025 Non-covered Recipient Entity
Weill Cornell Medical College
A Phase 1/2 Open-Label Study of the Safety, Tolerability and Efficacy of the Selective Inhibitor of Nuclear Export (SINE) Compound KPT-8602 in Patients with Relapsed, Refractory Cancer Indications No dispute reported 06/30/2026 1246667341
Principal investigator 1 Karyopharm Therapeutics Inc. $133.00 06/13/2025 Non-covered Recipient Entity
Weill Cornell Medical College
A Phase 1/2 Open-Label Study of the Safety, Tolerability and Efficacy of the Selective Inhibitor of Nuclear Export (SINE) Compound KPT-8602 in Patients with Relapsed, Refractory Cancer Indications No dispute reported 06/30/2026 1246667343
Principal investigator 1 Karyopharm Therapeutics Inc. $283.00 06/13/2025 Non-covered Recipient Entity
Weill Cornell Medical College
A Phase 1/2 Open-Label Study of the Safety, Tolerability and Efficacy of the Selective Inhibitor of Nuclear Export (SINE) Compound KPT-8602 in Patients with Relapsed, Refractory Cancer Indications No dispute reported 06/30/2026 1246667345
Principal investigator 1 Karyopharm Therapeutics Inc. $170.00 06/13/2025 Non-covered Recipient Entity
Weill Cornell Medical College
A Phase 1/2 Open-Label Study of the Safety, Tolerability and Efficacy of the Selective Inhibitor of Nuclear Export (SINE) Compound KPT-8602 in Patients with Relapsed, Refractory Cancer Indications No dispute reported 06/30/2026 1246667347
Principal investigator 1 Karyopharm Therapeutics Inc. $170.00 06/13/2025 Non-covered Recipient Entity
Weill Cornell Medical College
A Phase 1/2 Open-Label Study of the Safety, Tolerability and Efficacy of the Selective Inhibitor of Nuclear Export (SINE) Compound KPT-8602 in Patients with Relapsed, Refractory Cancer Indications No dispute reported 06/30/2026 1246667349
Principal investigator 1 Karyopharm Therapeutics Inc. $170.00 06/13/2025 Non-covered Recipient Entity
Weill Cornell Medical College
A Phase 1/2 Open-Label Study of the Safety, Tolerability and Efficacy of the Selective Inhibitor of Nuclear Export (SINE) Compound KPT-8602 in Patients with Relapsed, Refractory Cancer Indications No dispute reported 06/30/2026 1246667351
Principal investigator 1 Karyopharm Therapeutics Inc. $293.00 06/13/2025 Non-covered Recipient Entity
Weill Cornell Medical College
A Phase 1/2 Open-Label Study of the Safety, Tolerability and Efficacy of the Selective Inhibitor of Nuclear Export (SINE) Compound KPT-8602 in Patients with Relapsed, Refractory Cancer Indications No dispute reported 06/30/2026 1246667354
Principal investigator 1 Karyopharm Therapeutics Inc. $311.00 06/13/2025 Non-covered Recipient Entity
Weill Cornell Medical College
A Phase 1/2 Open-Label Study of the Safety, Tolerability and Efficacy of the Selective Inhibitor of Nuclear Export (SINE) Compound KPT-8602 in Patients with Relapsed, Refractory Cancer Indications No dispute reported 06/30/2026 1246667356
Principal investigator 1 Karyopharm Therapeutics Inc. $46.55 06/13/2025 Non-covered Recipient Entity
Weill Cornell Medical College
A Phase 1/2 Open-Label Study of the Safety, Tolerability and Efficacy of the Selective Inhibitor of Nuclear Export (SINE) Compound KPT-8602 in Patients with Relapsed, Refractory Cancer Indications No dispute reported 06/30/2026 1246667358
Principal investigator 1 Karyopharm Therapeutics Inc. $170.00 06/13/2025 Non-covered Recipient Entity
Weill Cornell Medical College
A Phase 1/2 Open-Label Study of the Safety, Tolerability and Efficacy of the Selective Inhibitor of Nuclear Export (SINE) Compound KPT-8602 in Patients with Relapsed, Refractory Cancer Indications No dispute reported 06/30/2026 1246667360
Principal investigator 1 Karyopharm Therapeutics Inc. $170.00 06/13/2025 Non-covered Recipient Entity
Weill Cornell Medical College
A Phase 1/2 Open-Label Study of the Safety, Tolerability and Efficacy of the Selective Inhibitor of Nuclear Export (SINE) Compound KPT-8602 in Patients with Relapsed, Refractory Cancer Indications No dispute reported 06/30/2026 1246667362
Principal investigator 1 Karyopharm Therapeutics Inc. $100.00 06/13/2025 Non-covered Recipient Entity
Weill Cornell Medical College
A Phase 1/2 Open-Label Study of the Safety, Tolerability and Efficacy of the Selective Inhibitor of Nuclear Export (SINE) Compound KPT-8602 in Patients with Relapsed, Refractory Cancer Indications No dispute reported 06/30/2026 1246667364
Principal investigator 1 Karyopharm Therapeutics Inc. $133.00 06/13/2025 Non-covered Recipient Entity
Weill Cornell Medical College
A Phase 1/2 Open-Label Study of the Safety, Tolerability and Efficacy of the Selective Inhibitor of Nuclear Export (SINE) Compound KPT-8602 in Patients with Relapsed, Refractory Cancer Indications No dispute reported 06/30/2026 1246667366
Principal investigator 1 Karyopharm Therapeutics Inc. $266.00 06/13/2025 Non-covered Recipient Entity
Weill Cornell Medical College
A Phase 1/2 Open-Label Study of the Safety, Tolerability and Efficacy of the Selective Inhibitor of Nuclear Export (SINE) Compound KPT-8602 in Patients with Relapsed, Refractory Cancer Indications No dispute reported 06/30/2026 1246667368
Principal investigator 1 Karyopharm Therapeutics Inc. $170.00 06/13/2025 Non-covered Recipient Entity
Weill Cornell Medical College
A Phase 1/2 Open-Label Study of the Safety, Tolerability and Efficacy of the Selective Inhibitor of Nuclear Export (SINE) Compound KPT-8602 in Patients with Relapsed, Refractory Cancer Indications No dispute reported 06/30/2026 1246667370
Principal investigator 1 Karyopharm Therapeutics Inc. $41.23 06/13/2025 Non-covered Recipient Entity
Weill Cornell Medical College
A Phase 1/2 Open-Label Study of the Safety, Tolerability and Efficacy of the Selective Inhibitor of Nuclear Export (SINE) Compound KPT-8602 in Patients with Relapsed, Refractory Cancer Indications No dispute reported 06/30/2026 1246667372
Principal investigator 1 Karyopharm Therapeutics Inc. $170.00 06/13/2025 Non-covered Recipient Entity
Weill Cornell Medical College
A Phase 1/2 Open-Label Study of the Safety, Tolerability and Efficacy of the Selective Inhibitor of Nuclear Export (SINE) Compound KPT-8602 in Patients with Relapsed, Refractory Cancer Indications No dispute reported 06/30/2026 1246667374
Principal investigator 1 Karyopharm Therapeutics Inc. $170.00 06/13/2025 Non-covered Recipient Entity
Weill Cornell Medical College
A Phase 1/2 Open-Label Study of the Safety, Tolerability and Efficacy of the Selective Inhibitor of Nuclear Export (SINE) Compound KPT-8602 in Patients with Relapsed, Refractory Cancer Indications No dispute reported 06/30/2026 1246667376
Principal investigator 1 Karyopharm Therapeutics Inc. $41.23 06/13/2025 Non-covered Recipient Entity
Weill Cornell Medical College
A Phase 1/2 Open-Label Study of the Safety, Tolerability and Efficacy of the Selective Inhibitor of Nuclear Export (SINE) Compound KPT-8602 in Patients with Relapsed, Refractory Cancer Indications No dispute reported 06/30/2026 1246667378
Principal investigator 1 Karyopharm Therapeutics Inc. $41.23 06/13/2025 Non-covered Recipient Entity
Weill Cornell Medical College
A Phase 1/2 Open-Label Study of the Safety, Tolerability and Efficacy of the Selective Inhibitor of Nuclear Export (SINE) Compound KPT-8602 in Patients with Relapsed, Refractory Cancer Indications No dispute reported 06/30/2026 1246667380
Principal investigator 1 Karyopharm Therapeutics Inc. $170.00 06/13/2025 Non-covered Recipient Entity
Weill Cornell Medical College
A Phase 1/2 Open-Label Study of the Safety, Tolerability and Efficacy of the Selective Inhibitor of Nuclear Export (SINE) Compound KPT-8602 in Patients with Relapsed, Refractory Cancer Indications No dispute reported 06/30/2026 1246667382
Principal investigator 1 Karyopharm Therapeutics Inc. $1,000.00 06/13/2025 Non-covered Recipient Entity
Weill Cornell Medical College
A Phase 1/2 Open-Label Study of the Safety, Tolerability and Efficacy of the Selective Inhibitor of Nuclear Export (SINE) Compound KPT-8602 in Patients with Relapsed, Refractory Cancer Indications No dispute reported 06/30/2026 1246667384
Principal investigator 1 Karyopharm Therapeutics Inc. $170.00 06/13/2025 Non-covered Recipient Entity
Weill Cornell Medical College
A Phase 1/2 Open-Label Study of the Safety, Tolerability and Efficacy of the Selective Inhibitor of Nuclear Export (SINE) Compound KPT-8602 in Patients with Relapsed, Refractory Cancer Indications No dispute reported 06/30/2026 1246667386
Principal investigator 1 Karyopharm Therapeutics Inc. $320.00 06/13/2025 Non-covered Recipient Entity
Weill Cornell Medical College
A Phase 1/2 Open-Label Study of the Safety, Tolerability and Efficacy of the Selective Inhibitor of Nuclear Export (SINE) Compound KPT-8602 in Patients with Relapsed, Refractory Cancer Indications No dispute reported 06/30/2026 1246667388
Principal investigator 1 Karyopharm Therapeutics Inc. $133.00 06/13/2025 Non-covered Recipient Entity
Weill Cornell Medical College
A Phase 1/2 Open-Label Study of the Safety, Tolerability and Efficacy of the Selective Inhibitor of Nuclear Export (SINE) Compound KPT-8602 in Patients with Relapsed, Refractory Cancer Indications No dispute reported 06/30/2026 1246667390
Principal investigator 1 Karyopharm Therapeutics Inc. $170.00 06/13/2025 Non-covered Recipient Entity
Weill Cornell Medical College
A Phase 1/2 Open-Label Study of the Safety, Tolerability and Efficacy of the Selective Inhibitor of Nuclear Export (SINE) Compound KPT-8602 in Patients with Relapsed, Refractory Cancer Indications No dispute reported 06/30/2026 1246667392
Principal investigator 1 Karyopharm Therapeutics Inc. $100.00 06/13/2025 Non-covered Recipient Entity
Weill Cornell Medical College
A Phase 1/2 Open-Label Study of the Safety, Tolerability and Efficacy of the Selective Inhibitor of Nuclear Export (SINE) Compound KPT-8602 in Patients with Relapsed, Refractory Cancer Indications No dispute reported 06/30/2026 1246667394
Principal investigator 1 Karyopharm Therapeutics Inc. $170.00 06/13/2025 Non-covered Recipient Entity
Weill Cornell Medical College
A Phase 1/2 Open-Label Study of the Safety, Tolerability and Efficacy of the Selective Inhibitor of Nuclear Export (SINE) Compound KPT-8602 in Patients with Relapsed, Refractory Cancer Indications No dispute reported 06/30/2026 1246667396
Principal investigator 1 Karyopharm Therapeutics Inc. $170.00 06/13/2025 Non-covered Recipient Entity
Weill Cornell Medical College
A Phase 1/2 Open-Label Study of the Safety, Tolerability and Efficacy of the Selective Inhibitor of Nuclear Export (SINE) Compound KPT-8602 in Patients with Relapsed, Refractory Cancer Indications No dispute reported 06/30/2026 1246667398
Principal investigator 1 Karyopharm Therapeutics Inc. $100.00 06/13/2025 Non-covered Recipient Entity
Weill Cornell Medical College
A Phase 1/2 Open-Label Study of the Safety, Tolerability and Efficacy of the Selective Inhibitor of Nuclear Export (SINE) Compound KPT-8602 in Patients with Relapsed, Refractory Cancer Indications No dispute reported 06/30/2026 1246667400
Principal investigator 1 Karyopharm Therapeutics Inc. $70.00 06/13/2025 Non-covered Recipient Entity
Weill Cornell Medical College
A Phase 1/2 Open-Label Study of the Safety, Tolerability and Efficacy of the Selective Inhibitor of Nuclear Export (SINE) Compound KPT-8602 in Patients with Relapsed, Refractory Cancer Indications No dispute reported 06/30/2026 1246667402
Principal investigator 1 Karyopharm Therapeutics Inc. $1,750.00 06/13/2025 Non-covered Recipient Entity
Weill Cornell Medical College
A Phase 1/2 Open-Label Study of the Safety, Tolerability and Efficacy of the Selective Inhibitor of Nuclear Export (SINE) Compound KPT-8602 in Patients with Relapsed, Refractory Cancer Indications No dispute reported 06/30/2026 1246667404
Principal investigator 1 Karyopharm Therapeutics Inc. $133.00 06/13/2025 Non-covered Recipient Entity
Weill Cornell Medical College
A Phase 1/2 Open-Label Study of the Safety, Tolerability and Efficacy of the Selective Inhibitor of Nuclear Export (SINE) Compound KPT-8602 in Patients with Relapsed, Refractory Cancer Indications No dispute reported 06/30/2026 1246667406
Principal investigator 1 Karyopharm Therapeutics Inc. $311.00 06/13/2025 Non-covered Recipient Entity
Weill Cornell Medical College
A Phase 1/2 Open-Label Study of the Safety, Tolerability and Efficacy of the Selective Inhibitor of Nuclear Export (SINE) Compound KPT-8602 in Patients with Relapsed, Refractory Cancer Indications No dispute reported 06/30/2026 1246667408
Principal investigator 1 Karyopharm Therapeutics Inc. $266.00 06/13/2025 Non-covered Recipient Entity
Weill Cornell Medical College
A Phase 1/2 Open-Label Study of the Safety, Tolerability and Efficacy of the Selective Inhibitor of Nuclear Export (SINE) Compound KPT-8602 in Patients with Relapsed, Refractory Cancer Indications No dispute reported 06/30/2026 1246667410
Principal investigator 1 Karyopharm Therapeutics Inc. $303.00 06/13/2025 Non-covered Recipient Entity
Weill Cornell Medical College
A Phase 1/2 Open-Label Study of the Safety, Tolerability and Efficacy of the Selective Inhibitor of Nuclear Export (SINE) Compound KPT-8602 in Patients with Relapsed, Refractory Cancer Indications No dispute reported 06/30/2026 1246667412
Principal investigator 1 Karyopharm Therapeutics Inc. $266.00 06/13/2025 Non-covered Recipient Entity
Weill Cornell Medical College
A Phase 1/2 Open-Label Study of the Safety, Tolerability and Efficacy of the Selective Inhibitor of Nuclear Export (SINE) Compound KPT-8602 in Patients with Relapsed, Refractory Cancer Indications No dispute reported 06/30/2026 1246667414
Principal investigator 1 Karyopharm Therapeutics Inc. $100.00 06/13/2025 Non-covered Recipient Entity
Weill Cornell Medical College
A Phase 1/2 Open-Label Study of the Safety, Tolerability and Efficacy of the Selective Inhibitor of Nuclear Export (SINE) Compound KPT-8602 in Patients with Relapsed, Refractory Cancer Indications No dispute reported 06/30/2026 1246667416
Principal investigator 1 Karyopharm Therapeutics Inc. $170.00 06/13/2025 Non-covered Recipient Entity
Weill Cornell Medical College
A Phase 1/2 Open-Label Study of the Safety, Tolerability and Efficacy of the Selective Inhibitor of Nuclear Export (SINE) Compound KPT-8602 in Patients with Relapsed, Refractory Cancer Indications No dispute reported 06/30/2026 1246667418
Principal investigator 1 Karyopharm Therapeutics Inc. $170.00 06/13/2025 Non-covered Recipient Entity
Weill Cornell Medical College
A Phase 1/2 Open-Label Study of the Safety, Tolerability and Efficacy of the Selective Inhibitor of Nuclear Export (SINE) Compound KPT-8602 in Patients with Relapsed, Refractory Cancer Indications No dispute reported 06/30/2026 1246667420
Principal investigator 1 Karyopharm Therapeutics Inc. $320.00 06/13/2025 Non-covered Recipient Entity
Weill Cornell Medical College
A Phase 1/2 Open-Label Study of the Safety, Tolerability and Efficacy of the Selective Inhibitor of Nuclear Export (SINE) Compound KPT-8602 in Patients with Relapsed, Refractory Cancer Indications No dispute reported 06/30/2026 1246667422
Principal investigator 1 Karyopharm Therapeutics Inc. $311.00 06/13/2025 Non-covered Recipient Entity
Weill Cornell Medical College
A Phase 1/2 Open-Label Study of the Safety, Tolerability and Efficacy of the Selective Inhibitor of Nuclear Export (SINE) Compound KPT-8602 in Patients with Relapsed, Refractory Cancer Indications No dispute reported 06/30/2026 1246667424
Principal investigator 1 Karyopharm Therapeutics Inc. $170.00 06/13/2025 Non-covered Recipient Entity
Weill Cornell Medical College
A Phase 1/2 Open-Label Study of the Safety, Tolerability and Efficacy of the Selective Inhibitor of Nuclear Export (SINE) Compound KPT-8602 in Patients with Relapsed, Refractory Cancer Indications No dispute reported 06/30/2026 1246667426
Principal investigator 1 Karyopharm Therapeutics Inc. $133.00 06/13/2025 Non-covered Recipient Entity
Weill Cornell Medical College
A Phase 1/2 Open-Label Study of the Safety, Tolerability and Efficacy of the Selective Inhibitor of Nuclear Export (SINE) Compound KPT-8602 in Patients with Relapsed, Refractory Cancer Indications No dispute reported 06/30/2026 1246667428
Principal investigator 1 Karyopharm Therapeutics Inc. $283.00 06/13/2025 Non-covered Recipient Entity
Weill Cornell Medical College
A Phase 1/2 Open-Label Study of the Safety, Tolerability and Efficacy of the Selective Inhibitor of Nuclear Export (SINE) Compound KPT-8602 in Patients with Relapsed, Refractory Cancer Indications No dispute reported 06/30/2026 1246667430
Principal investigator 1 Karyopharm Therapeutics Inc. $70.00 06/13/2025 Non-covered Recipient Entity
Weill Cornell Medical College
A Phase 1/2 Open-Label Study of the Safety, Tolerability and Efficacy of the Selective Inhibitor of Nuclear Export (SINE) Compound KPT-8602 in Patients with Relapsed, Refractory Cancer Indications No dispute reported 06/30/2026 1246667432
Principal investigator 1 Karyopharm Therapeutics Inc. $100.00 06/13/2025 Non-covered Recipient Entity
Weill Cornell Medical College
A Phase 1/2 Open-Label Study of the Safety, Tolerability and Efficacy of the Selective Inhibitor of Nuclear Export (SINE) Compound KPT-8602 in Patients with Relapsed, Refractory Cancer Indications No dispute reported 06/30/2026 1246667434
Principal investigator 1 Karyopharm Therapeutics Inc. $100.00 06/13/2025 Non-covered Recipient Entity
Weill Cornell Medical College
A Phase 1/2 Open-Label Study of the Safety, Tolerability and Efficacy of the Selective Inhibitor of Nuclear Export (SINE) Compound KPT-8602 in Patients with Relapsed, Refractory Cancer Indications No dispute reported 06/30/2026 1246667436
Principal investigator 1 Karyopharm Therapeutics Inc. $170.00 06/13/2025 Non-covered Recipient Entity
Weill Cornell Medical College
A Phase 1/2 Open-Label Study of the Safety, Tolerability and Efficacy of the Selective Inhibitor of Nuclear Export (SINE) Compound KPT-8602 in Patients with Relapsed, Refractory Cancer Indications No dispute reported 06/30/2026 1246667438
Principal investigator 1 Karyopharm Therapeutics Inc. $170.00 06/13/2025 Non-covered Recipient Entity
Weill Cornell Medical College
A Phase 1/2 Open-Label Study of the Safety, Tolerability and Efficacy of the Selective Inhibitor of Nuclear Export (SINE) Compound KPT-8602 in Patients with Relapsed, Refractory Cancer Indications No dispute reported 06/30/2026 1246667440
Principal investigator 1 Karyopharm Therapeutics Inc. $170.00 06/13/2025 Non-covered Recipient Entity
Weill Cornell Medical College
A Phase 1/2 Open-Label Study of the Safety, Tolerability and Efficacy of the Selective Inhibitor of Nuclear Export (SINE) Compound KPT-8602 in Patients with Relapsed, Refractory Cancer Indications No dispute reported 06/30/2026 1246667442
Principal investigator 1 Karyopharm Therapeutics Inc. $266.00 06/13/2025 Non-covered Recipient Entity
Weill Cornell Medical College
A Phase 1/2 Open-Label Study of the Safety, Tolerability and Efficacy of the Selective Inhibitor of Nuclear Export (SINE) Compound KPT-8602 in Patients with Relapsed, Refractory Cancer Indications No dispute reported 06/30/2026 1246667444
Principal investigator 1 Karyopharm Therapeutics Inc. $133.00 06/13/2025 Non-covered Recipient Entity
Weill Cornell Medical College
A Phase 1/2 Open-Label Study of the Safety, Tolerability and Efficacy of the Selective Inhibitor of Nuclear Export (SINE) Compound KPT-8602 in Patients with Relapsed, Refractory Cancer Indications No dispute reported 06/30/2026 1246667446
Principal investigator 1 Karyopharm Therapeutics Inc. $283.00 06/13/2025 Non-covered Recipient Entity
Weill Cornell Medical College
A Phase 1/2 Open-Label Study of the Safety, Tolerability and Efficacy of the Selective Inhibitor of Nuclear Export (SINE) Compound KPT-8602 in Patients with Relapsed, Refractory Cancer Indications No dispute reported 06/30/2026 1246667448
Principal investigator 1 Karyopharm Therapeutics Inc. $170.00 06/13/2025 Non-covered Recipient Entity
Weill Cornell Medical College
A Phase 1/2 Open-Label Study of the Safety, Tolerability and Efficacy of the Selective Inhibitor of Nuclear Export (SINE) Compound KPT-8602 in Patients with Relapsed, Refractory Cancer Indications No dispute reported 06/30/2026 1246667450
Principal investigator 1 Karyopharm Therapeutics Inc. $1,254.15 06/13/2025 Non-covered Recipient Entity
Weill Cornell Medical College
A Phase 1/2 Open-Label Study of the Safety, Tolerability and Efficacy of the Selective Inhibitor of Nuclear Export (SINE) Compound KPT-8602 in Patients with Relapsed, Refractory Cancer Indications No dispute reported 06/30/2026 1246667452
Principal investigator 1 Karyopharm Therapeutics Inc. $46.55 06/13/2025 Non-covered Recipient Entity
Weill Cornell Medical College
A Phase 1/2 Open-Label Study of the Safety, Tolerability and Efficacy of the Selective Inhibitor of Nuclear Export (SINE) Compound KPT-8602 in Patients with Relapsed, Refractory Cancer Indications No dispute reported 06/30/2026 1246667454
Principal investigator 1 Karyopharm Therapeutics Inc. $46.55 06/13/2025 Non-covered Recipient Entity
Weill Cornell Medical College
A Phase 1/2 Open-Label Study of the Safety, Tolerability and Efficacy of the Selective Inhibitor of Nuclear Export (SINE) Compound KPT-8602 in Patients with Relapsed, Refractory Cancer Indications No dispute reported 06/30/2026 1246667456
Principal investigator 1 Karyopharm Therapeutics Inc. $133.00 06/13/2025 Non-covered Recipient Entity
Weill Cornell Medical College
A Phase 1/2 Open-Label Study of the Safety, Tolerability and Efficacy of the Selective Inhibitor of Nuclear Export (SINE) Compound KPT-8602 in Patients with Relapsed, Refractory Cancer Indications No dispute reported 06/30/2026 1246667458
Principal investigator 1 Karyopharm Therapeutics Inc. $170.00 06/13/2025 Non-covered Recipient Entity
Weill Cornell Medical College
A Phase 1/2 Open-Label Study of the Safety, Tolerability and Efficacy of the Selective Inhibitor of Nuclear Export (SINE) Compound KPT-8602 in Patients with Relapsed, Refractory Cancer Indications No dispute reported 06/30/2026 1246667460
Principal investigator 1 Karyopharm Therapeutics Inc. $41.23 06/13/2025 Non-covered Recipient Entity
Weill Cornell Medical College
A Phase 1/2 Open-Label Study of the Safety, Tolerability and Efficacy of the Selective Inhibitor of Nuclear Export (SINE) Compound KPT-8602 in Patients with Relapsed, Refractory Cancer Indications No dispute reported 06/30/2026 1246667462
Principal investigator 1 Karyopharm Therapeutics Inc. $133.00 06/13/2025 Non-covered Recipient Entity
Weill Cornell Medical College
A Phase 1/2 Open-Label Study of the Safety, Tolerability and Efficacy of the Selective Inhibitor of Nuclear Export (SINE) Compound KPT-8602 in Patients with Relapsed, Refractory Cancer Indications No dispute reported 06/30/2026 1246667464
Principal investigator 1 Karyopharm Therapeutics Inc. $266.00 06/13/2025 Non-covered Recipient Entity
Weill Cornell Medical College
A Phase 1/2 Open-Label Study of the Safety, Tolerability and Efficacy of the Selective Inhibitor of Nuclear Export (SINE) Compound KPT-8602 in Patients with Relapsed, Refractory Cancer Indications No dispute reported 06/30/2026 1246667466
Principal investigator 1 Karyopharm Therapeutics Inc. $100.00 06/13/2025 Non-covered Recipient Entity
Weill Cornell Medical College
A Phase 1/2 Open-Label Study of the Safety, Tolerability and Efficacy of the Selective Inhibitor of Nuclear Export (SINE) Compound KPT-8602 in Patients with Relapsed, Refractory Cancer Indications No dispute reported 06/30/2026 1246667468
Principal investigator 1 Karyopharm Therapeutics Inc. $100.00 06/13/2025 Non-covered Recipient Entity
Weill Cornell Medical College
A Phase 1/2 Open-Label Study of the Safety, Tolerability and Efficacy of the Selective Inhibitor of Nuclear Export (SINE) Compound KPT-8602 in Patients with Relapsed, Refractory Cancer Indications No dispute reported 06/30/2026 1246667470
Principal investigator 1 Karyopharm Therapeutics Inc. $300.00 06/13/2025 Non-covered Recipient Entity
Weill Cornell Medical College
A Phase 1/2 Open-Label Study of the Safety, Tolerability and Efficacy of the Selective Inhibitor of Nuclear Export (SINE) Compound KPT-8602 in Patients with Relapsed, Refractory Cancer Indications No dispute reported 06/30/2026 1246667472
Principal investigator 1 Karyopharm Therapeutics Inc. $100.00 06/13/2025 Non-covered Recipient Entity
Weill Cornell Medical College
A Phase 1/2 Open-Label Study of the Safety, Tolerability and Efficacy of the Selective Inhibitor of Nuclear Export (SINE) Compound KPT-8602 in Patients with Relapsed, Refractory Cancer Indications No dispute reported 06/30/2026 1246667474
Principal investigator 1 Karyopharm Therapeutics Inc. $42.56 06/13/2025 Non-covered Recipient Entity
Weill Cornell Medical College
A Phase 1/2 Open-Label Study of the Safety, Tolerability and Efficacy of the Selective Inhibitor of Nuclear Export (SINE) Compound KPT-8602 in Patients with Relapsed, Refractory Cancer Indications No dispute reported 06/30/2026 1246667476
Principal investigator 1 Karyopharm Therapeutics Inc. $170.00 06/13/2025 Non-covered Recipient Entity
Weill Cornell Medical College
A Phase 1/2 Open-Label Study of the Safety, Tolerability and Efficacy of the Selective Inhibitor of Nuclear Export (SINE) Compound KPT-8602 in Patients with Relapsed, Refractory Cancer Indications No dispute reported 06/30/2026 1246667478
Principal investigator 1 Karyopharm Therapeutics Inc. $199.50 06/13/2025 Non-covered Recipient Entity
Weill Cornell Medical College
A Phase 1/2 Open-Label Study of the Safety, Tolerability and Efficacy of the Selective Inhibitor of Nuclear Export (SINE) Compound KPT-8602 in Patients with Relapsed, Refractory Cancer Indications No dispute reported 06/30/2026 1246667480
Principal investigator 1 Karyopharm Therapeutics Inc. $170.00 06/13/2025 Non-covered Recipient Entity
Weill Cornell Medical College
A Phase 1/2 Open-Label Study of the Safety, Tolerability and Efficacy of the Selective Inhibitor of Nuclear Export (SINE) Compound KPT-8602 in Patients with Relapsed, Refractory Cancer Indications No dispute reported 06/30/2026 1246667482
Principal investigator 1 Karyopharm Therapeutics Inc. $1,750.00 06/13/2025 Non-covered Recipient Entity
Weill Cornell Medical College
A Phase 1/2 Open-Label Study of the Safety, Tolerability and Efficacy of the Selective Inhibitor of Nuclear Export (SINE) Compound KPT-8602 in Patients with Relapsed, Refractory Cancer Indications No dispute reported 06/30/2026 1246667484
Principal investigator 1 Karyopharm Therapeutics Inc. $170.00 06/13/2025 Non-covered Recipient Entity
Weill Cornell Medical College
A Phase 1/2 Open-Label Study of the Safety, Tolerability and Efficacy of the Selective Inhibitor of Nuclear Export (SINE) Compound KPT-8602 in Patients with Relapsed, Refractory Cancer Indications No dispute reported 06/30/2026 1246667486
Principal investigator 1 Karyopharm Therapeutics Inc. $42.56 06/13/2025 Non-covered Recipient Entity
Weill Cornell Medical College
A Phase 1/2 Open-Label Study of the Safety, Tolerability and Efficacy of the Selective Inhibitor of Nuclear Export (SINE) Compound KPT-8602 in Patients with Relapsed, Refractory Cancer Indications No dispute reported 06/30/2026 1246667488
Principal investigator 1 Karyopharm Therapeutics Inc. $600.50 06/13/2025 Non-covered Recipient Entity
Weill Cornell Medical College
A Phase 1/2 Open-Label Study of the Safety, Tolerability and Efficacy of the Selective Inhibitor of Nuclear Export (SINE) Compound KPT-8602 in Patients with Relapsed, Refractory Cancer Indications No dispute reported 06/30/2026 1246667490
Principal investigator 1 Karyopharm Therapeutics Inc. $488.00 06/13/2025 Non-covered Recipient Entity
Weill Cornell Medical College
A Phase 1/2 Open-Label Study of the Safety, Tolerability and Efficacy of the Selective Inhibitor of Nuclear Export (SINE) Compound KPT-8602 in Patients with Relapsed, Refractory Cancer Indications No dispute reported 06/30/2026 1246667492
Principal investigator 1 Karyopharm Therapeutics Inc. $170.00 06/13/2025 Non-covered Recipient Entity
Weill Cornell Medical College
A Phase 1/2 Open-Label Study of the Safety, Tolerability and Efficacy of the Selective Inhibitor of Nuclear Export (SINE) Compound KPT-8602 in Patients with Relapsed, Refractory Cancer Indications No dispute reported 06/30/2026 1246667494
Principal investigator 1 Karyopharm Therapeutics Inc. $46.55 06/13/2025 Non-covered Recipient Entity
Weill Cornell Medical College
A Phase 1/2 Open-Label Study of the Safety, Tolerability and Efficacy of the Selective Inhibitor of Nuclear Export (SINE) Compound KPT-8602 in Patients with Relapsed, Refractory Cancer Indications No dispute reported 06/30/2026 1246667496
Principal investigator 1 Karyopharm Therapeutics Inc. $170.00 06/13/2025 Non-covered Recipient Entity
Weill Cornell Medical College
A Phase 1/2 Open-Label Study of the Safety, Tolerability and Efficacy of the Selective Inhibitor of Nuclear Export (SINE) Compound KPT-8602 in Patients with Relapsed, Refractory Cancer Indications No dispute reported 06/30/2026 1246667498
Principal investigator 1 Karyopharm Therapeutics Inc. $100.00 06/13/2025 Non-covered Recipient Entity
Weill Cornell Medical College
A Phase 1/2 Open-Label Study of the Safety, Tolerability and Efficacy of the Selective Inhibitor of Nuclear Export (SINE) Compound KPT-8602 in Patients with Relapsed, Refractory Cancer Indications No dispute reported 06/30/2026 1246667500
Principal investigator 1 Karyopharm Therapeutics Inc. $46.55 06/13/2025 Non-covered Recipient Entity
Weill Cornell Medical College
A Phase 1/2 Open-Label Study of the Safety, Tolerability and Efficacy of the Selective Inhibitor of Nuclear Export (SINE) Compound KPT-8602 in Patients with Relapsed, Refractory Cancer Indications No dispute reported 06/30/2026 1246667502
Principal investigator 1 Karyopharm Therapeutics Inc. $70.00 06/13/2025 Non-covered Recipient Entity
Weill Cornell Medical College
A Phase 1/2 Open-Label Study of the Safety, Tolerability and Efficacy of the Selective Inhibitor of Nuclear Export (SINE) Compound KPT-8602 in Patients with Relapsed, Refractory Cancer Indications No dispute reported 06/30/2026 1246667504
Principal investigator 1 Karyopharm Therapeutics Inc. $133.00 06/13/2025 Non-covered Recipient Entity
Weill Cornell Medical College
A Phase 1/2 Open-Label Study of the Safety, Tolerability and Efficacy of the Selective Inhibitor of Nuclear Export (SINE) Compound KPT-8602 in Patients with Relapsed, Refractory Cancer Indications No dispute reported 06/30/2026 1246667506
Principal investigator 1 Karyopharm Therapeutics Inc. $100.00 06/13/2025 Non-covered Recipient Entity
Weill Cornell Medical College
A Phase 1/2 Open-Label Study of the Safety, Tolerability and Efficacy of the Selective Inhibitor of Nuclear Export (SINE) Compound KPT-8602 in Patients with Relapsed, Refractory Cancer Indications No dispute reported 06/30/2026 1246667508
Principal investigator 1 Karyopharm Therapeutics Inc. $311.00 06/13/2025 Non-covered Recipient Entity
Weill Cornell Medical College
A Phase 1/2 Open-Label Study of the Safety, Tolerability and Efficacy of the Selective Inhibitor of Nuclear Export (SINE) Compound KPT-8602 in Patients with Relapsed, Refractory Cancer Indications No dispute reported 06/30/2026 1246667510
Principal investigator 1 Karyopharm Therapeutics Inc. $170.00 06/13/2025 Non-covered Recipient Entity
Weill Cornell Medical College
A Phase 1/2 Open-Label Study of the Safety, Tolerability and Efficacy of the Selective Inhibitor of Nuclear Export (SINE) Compound KPT-8602 in Patients with Relapsed, Refractory Cancer Indications No dispute reported 06/30/2026 1246667512
Principal investigator 1 Karyopharm Therapeutics Inc. $150.00 06/13/2025 Non-covered Recipient Entity
Weill Cornell Medical College
A Phase 1/2 Open-Label Study of the Safety, Tolerability and Efficacy of the Selective Inhibitor of Nuclear Export (SINE) Compound KPT-8602 in Patients with Relapsed, Refractory Cancer Indications No dispute reported 06/30/2026 1246667514
Principal investigator 1 Karyopharm Therapeutics Inc. $100.00 06/13/2025 Non-covered Recipient Entity
Weill Cornell Medical College
A Phase 1/2 Open-Label Study of the Safety, Tolerability and Efficacy of the Selective Inhibitor of Nuclear Export (SINE) Compound KPT-8602 in Patients with Relapsed, Refractory Cancer Indications No dispute reported 06/30/2026 1246667516
Principal investigator 1 Karyopharm Therapeutics Inc. $170.00 06/13/2025 Non-covered Recipient Entity
Weill Cornell Medical College
A Phase 1/2 Open-Label Study of the Safety, Tolerability and Efficacy of the Selective Inhibitor of Nuclear Export (SINE) Compound KPT-8602 in Patients with Relapsed, Refractory Cancer Indications No dispute reported 06/30/2026 1246667518
Principal investigator 1 Karyopharm Therapeutics Inc. $42.56 06/13/2025 Non-covered Recipient Entity
Weill Cornell Medical College
A Phase 1/2 Open-Label Study of the Safety, Tolerability and Efficacy of the Selective Inhibitor of Nuclear Export (SINE) Compound KPT-8602 in Patients with Relapsed, Refractory Cancer Indications No dispute reported 06/30/2026 1246667520
Principal investigator 1 Karyopharm Therapeutics Inc. $266.00 06/13/2025 Non-covered Recipient Entity
Weill Cornell Medical College
A Phase 1/2 Open-Label Study of the Safety, Tolerability and Efficacy of the Selective Inhibitor of Nuclear Export (SINE) Compound KPT-8602 in Patients with Relapsed, Refractory Cancer Indications No dispute reported 06/30/2026 1246667522
Principal investigator 1 Karyopharm Therapeutics Inc. $1,750.00 06/13/2025 Non-covered Recipient Entity
Weill Cornell Medical College
A Phase 1/2 Open-Label Study of the Safety, Tolerability and Efficacy of the Selective Inhibitor of Nuclear Export (SINE) Compound KPT-8602 in Patients with Relapsed, Refractory Cancer Indications No dispute reported 06/30/2026 1246667524
Principal investigator 1 Karyopharm Therapeutics Inc. $100.00 06/13/2025 Non-covered Recipient Entity
Weill Cornell Medical College
A Phase 1/2 Open-Label Study of the Safety, Tolerability and Efficacy of the Selective Inhibitor of Nuclear Export (SINE) Compound KPT-8602 in Patients with Relapsed, Refractory Cancer Indications No dispute reported 06/30/2026 1246667526
Principal investigator 1 Karyopharm Therapeutics Inc. $266.00 06/13/2025 Non-covered Recipient Entity
Weill Cornell Medical College
A Phase 1/2 Open-Label Study of the Safety, Tolerability and Efficacy of the Selective Inhibitor of Nuclear Export (SINE) Compound KPT-8602 in Patients with Relapsed, Refractory Cancer Indications No dispute reported 06/30/2026 1246667528
Principal investigator 1 Karyopharm Therapeutics Inc. $46.55 06/13/2025 Non-covered Recipient Entity
Weill Cornell Medical College
A Phase 1/2 Open-Label Study of the Safety, Tolerability and Efficacy of the Selective Inhibitor of Nuclear Export (SINE) Compound KPT-8602 in Patients with Relapsed, Refractory Cancer Indications No dispute reported 06/30/2026 1246667530
Principal investigator 1 Karyopharm Therapeutics Inc. $170.00 06/13/2025 Non-covered Recipient Entity
Weill Cornell Medical College
A Phase 1/2 Open-Label Study of the Safety, Tolerability and Efficacy of the Selective Inhibitor of Nuclear Export (SINE) Compound KPT-8602 in Patients with Relapsed, Refractory Cancer Indications No dispute reported 06/30/2026 1246667532
Principal investigator 1 Karyopharm Therapeutics Inc. $283.00 06/13/2025 Non-covered Recipient Entity
Weill Cornell Medical College
A Phase 1/2 Open-Label Study of the Safety, Tolerability and Efficacy of the Selective Inhibitor of Nuclear Export (SINE) Compound KPT-8602 in Patients with Relapsed, Refractory Cancer Indications No dispute reported 06/30/2026 1246667534
Principal investigator 1 Karyopharm Therapeutics Inc. $70.00 06/13/2025 Non-covered Recipient Entity
Weill Cornell Medical College
A Phase 1/2 Open-Label Study of the Safety, Tolerability and Efficacy of the Selective Inhibitor of Nuclear Export (SINE) Compound KPT-8602 in Patients with Relapsed, Refractory Cancer Indications No dispute reported 06/30/2026 1246667536
Principal investigator 1 Karyopharm Therapeutics Inc. $311.00 06/13/2025 Non-covered Recipient Entity
Weill Cornell Medical College
A Phase 1/2 Open-Label Study of the Safety, Tolerability and Efficacy of the Selective Inhibitor of Nuclear Export (SINE) Compound KPT-8602 in Patients with Relapsed, Refractory Cancer Indications No dispute reported 06/30/2026 1246667538
Principal investigator 1 Karyopharm Therapeutics Inc. $170.00 06/13/2025 Non-covered Recipient Entity
Weill Cornell Medical College
A Phase 1/2 Open-Label Study of the Safety, Tolerability and Efficacy of the Selective Inhibitor of Nuclear Export (SINE) Compound KPT-8602 in Patients with Relapsed, Refractory Cancer Indications No dispute reported 06/30/2026 1246667540
Principal investigator 1 Karyopharm Therapeutics Inc. $170.00 06/13/2025 Non-covered Recipient Entity
Weill Cornell Medical College
A Phase 1/2 Open-Label Study of the Safety, Tolerability and Efficacy of the Selective Inhibitor of Nuclear Export (SINE) Compound KPT-8602 in Patients with Relapsed, Refractory Cancer Indications No dispute reported 06/30/2026 1246667542
Principal investigator 1 Karyopharm Therapeutics Inc. $170.00 06/13/2025 Non-covered Recipient Entity
Weill Cornell Medical College
A Phase 1/2 Open-Label Study of the Safety, Tolerability and Efficacy of the Selective Inhibitor of Nuclear Export (SINE) Compound KPT-8602 in Patients with Relapsed, Refractory Cancer Indications No dispute reported 06/30/2026 1246667544
Principal investigator 1 Karyopharm Therapeutics Inc. $46.55 06/13/2025 Non-covered Recipient Entity
Weill Cornell Medical College
A Phase 1/2 Open-Label Study of the Safety, Tolerability and Efficacy of the Selective Inhibitor of Nuclear Export (SINE) Compound KPT-8602 in Patients with Relapsed, Refractory Cancer Indications No dispute reported 06/30/2026 1246667546
Principal investigator 1 Karyopharm Therapeutics Inc. $266.00 06/13/2025 Non-covered Recipient Entity
Weill Cornell Medical College
A Phase 1/2 Open-Label Study of the Safety, Tolerability and Efficacy of the Selective Inhibitor of Nuclear Export (SINE) Compound KPT-8602 in Patients with Relapsed, Refractory Cancer Indications No dispute reported 06/30/2026 1246667548
Principal investigator 1 Karyopharm Therapeutics Inc. $311.00 06/13/2025 Non-covered Recipient Entity
Weill Cornell Medical College
A Phase 1/2 Open-Label Study of the Safety, Tolerability and Efficacy of the Selective Inhibitor of Nuclear Export (SINE) Compound KPT-8602 in Patients with Relapsed, Refractory Cancer Indications No dispute reported 06/30/2026 1246667550
Principal investigator 1 Karyopharm Therapeutics Inc. $311.00 06/13/2025 Non-covered Recipient Entity
Weill Cornell Medical College
A Phase 1/2 Open-Label Study of the Safety, Tolerability and Efficacy of the Selective Inhibitor of Nuclear Export (SINE) Compound KPT-8602 in Patients with Relapsed, Refractory Cancer Indications No dispute reported 06/30/2026 1246667552
Principal investigator 1 Karyopharm Therapeutics Inc. $100.00 06/13/2025 Non-covered Recipient Entity
Weill Cornell Medical College
A Phase 1/2 Open-Label Study of the Safety, Tolerability and Efficacy of the Selective Inhibitor of Nuclear Export (SINE) Compound KPT-8602 in Patients with Relapsed, Refractory Cancer Indications No dispute reported 06/30/2026 1246667554
Principal investigator 1 Karyopharm Therapeutics Inc. $170.00 06/13/2025 Non-covered Recipient Entity
Weill Cornell Medical College
A Phase 1/2 Open-Label Study of the Safety, Tolerability and Efficacy of the Selective Inhibitor of Nuclear Export (SINE) Compound KPT-8602 in Patients with Relapsed, Refractory Cancer Indications No dispute reported 06/30/2026 1246667556
Principal investigator 1 Karyopharm Therapeutics Inc. $864.50 06/13/2025 Non-covered Recipient Entity
Weill Cornell Medical College
A Phase 1/2 Open-Label Study of the Safety, Tolerability and Efficacy of the Selective Inhibitor of Nuclear Export (SINE) Compound KPT-8602 in Patients with Relapsed, Refractory Cancer Indications No dispute reported 06/30/2026 1246667558
Principal investigator 1 Karyopharm Therapeutics Inc. $170.00 06/13/2025 Non-covered Recipient Entity
Weill Cornell Medical College
A Phase 1/2 Open-Label Study of the Safety, Tolerability and Efficacy of the Selective Inhibitor of Nuclear Export (SINE) Compound KPT-8602 in Patients with Relapsed, Refractory Cancer Indications No dispute reported 06/30/2026 1246667560
Principal investigator 1 Karyopharm Therapeutics Inc. $1,750.00 06/13/2025 Non-covered Recipient Entity
Weill Cornell Medical College
A Phase 1/2 Open-Label Study of the Safety, Tolerability and Efficacy of the Selective Inhibitor of Nuclear Export (SINE) Compound KPT-8602 in Patients with Relapsed, Refractory Cancer Indications No dispute reported 06/30/2026 1246667562
Principal investigator 1 Karyopharm Therapeutics Inc. $133.00 06/13/2025 Non-covered Recipient Entity
Weill Cornell Medical College
A Phase 1/2 Open-Label Study of the Safety, Tolerability and Efficacy of the Selective Inhibitor of Nuclear Export (SINE) Compound KPT-8602 in Patients with Relapsed, Refractory Cancer Indications No dispute reported 06/30/2026 1246667564
Principal investigator 1 Karyopharm Therapeutics Inc. $133.00 06/13/2025 Non-covered Recipient Entity
Weill Cornell Medical College
A Phase 1/2 Open-Label Study of the Safety, Tolerability and Efficacy of the Selective Inhibitor of Nuclear Export (SINE) Compound KPT-8602 in Patients with Relapsed, Refractory Cancer Indications No dispute reported 06/30/2026 1246667566
Principal investigator 1 Karyopharm Therapeutics Inc. $928.80 06/13/2025 Non-covered Recipient Entity
Weill Cornell Medical College
A Phase 1/2 Open-Label Study of the Safety, Tolerability and Efficacy of the Selective Inhibitor of Nuclear Export (SINE) Compound KPT-8602 in Patients with Relapsed, Refractory Cancer Indications No dispute reported 06/30/2026 1246667568
Principal investigator 1 Karyopharm Therapeutics Inc. $1,254.15 06/13/2025 Non-covered Recipient Entity
Weill Cornell Medical College
A Phase 1/2 Open-Label Study of the Safety, Tolerability and Efficacy of the Selective Inhibitor of Nuclear Export (SINE) Compound KPT-8602 in Patients with Relapsed, Refractory Cancer Indications No dispute reported 06/30/2026 1246667570
Principal investigator 1 Karyopharm Therapeutics Inc. $170.00 06/13/2025 Non-covered Recipient Entity
Weill Cornell Medical College
A Phase 1/2 Open-Label Study of the Safety, Tolerability and Efficacy of the Selective Inhibitor of Nuclear Export (SINE) Compound KPT-8602 in Patients with Relapsed, Refractory Cancer Indications No dispute reported 06/30/2026 1246667572
Principal investigator 1 Karyopharm Therapeutics Inc. $170.00 06/13/2025 Non-covered Recipient Entity
Weill Cornell Medical College
A Phase 1/2 Open-Label Study of the Safety, Tolerability and Efficacy of the Selective Inhibitor of Nuclear Export (SINE) Compound KPT-8602 in Patients with Relapsed, Refractory Cancer Indications No dispute reported 06/30/2026 1246667574
Principal investigator 1 Karyopharm Therapeutics Inc. $311.00 06/13/2025 Non-covered Recipient Entity
Weill Cornell Medical College
A Phase 1/2 Open-Label Study of the Safety, Tolerability and Efficacy of the Selective Inhibitor of Nuclear Export (SINE) Compound KPT-8602 in Patients with Relapsed, Refractory Cancer Indications No dispute reported 06/30/2026 1246667576
Principal investigator 1 Karyopharm Therapeutics Inc. $320.00 06/13/2025 Non-covered Recipient Entity
Weill Cornell Medical College
A Phase 1/2 Open-Label Study of the Safety, Tolerability and Efficacy of the Selective Inhibitor of Nuclear Export (SINE) Compound KPT-8602 in Patients with Relapsed, Refractory Cancer Indications No dispute reported 06/30/2026 1246667578
Principal investigator 1 Karyopharm Therapeutics Inc. $133.00 06/13/2025 Non-covered Recipient Entity
Weill Cornell Medical College
A Phase 1/2 Open-Label Study of the Safety, Tolerability and Efficacy of the Selective Inhibitor of Nuclear Export (SINE) Compound KPT-8602 in Patients with Relapsed, Refractory Cancer Indications No dispute reported 06/30/2026 1246667580
Principal investigator 1 Karyopharm Therapeutics Inc. $100.00 06/13/2025 Non-covered Recipient Entity
Weill Cornell Medical College
A Phase 1/2 Open-Label Study of the Safety, Tolerability and Efficacy of the Selective Inhibitor of Nuclear Export (SINE) Compound KPT-8602 in Patients with Relapsed, Refractory Cancer Indications No dispute reported 06/30/2026 1246667582
Principal investigator 1 Karyopharm Therapeutics Inc. $133.00 06/13/2025 Non-covered Recipient Entity
Weill Cornell Medical College
A Phase 1/2 Open-Label Study of the Safety, Tolerability and Efficacy of the Selective Inhibitor of Nuclear Export (SINE) Compound KPT-8602 in Patients with Relapsed, Refractory Cancer Indications No dispute reported 06/30/2026 1246667584
Principal investigator 1 Karyopharm Therapeutics Inc. $488.00 06/13/2025 Non-covered Recipient Entity
Weill Cornell Medical College
A Phase 1/2 Open-Label Study of the Safety, Tolerability and Efficacy of the Selective Inhibitor of Nuclear Export (SINE) Compound KPT-8602 in Patients with Relapsed, Refractory Cancer Indications No dispute reported 06/30/2026 1246667586
Principal investigator 1 Karyopharm Therapeutics Inc. $320.00 06/13/2025 Non-covered Recipient Entity
Weill Cornell Medical College
A Phase 1/2 Open-Label Study of the Safety, Tolerability and Efficacy of the Selective Inhibitor of Nuclear Export (SINE) Compound KPT-8602 in Patients with Relapsed, Refractory Cancer Indications No dispute reported 06/30/2026 1246667588
Principal investigator 1 Karyopharm Therapeutics Inc. $170.00 06/13/2025 Non-covered Recipient Entity
Weill Cornell Medical College
A Phase 1/2 Open-Label Study of the Safety, Tolerability and Efficacy of the Selective Inhibitor of Nuclear Export (SINE) Compound KPT-8602 in Patients with Relapsed, Refractory Cancer Indications No dispute reported 06/30/2026 1246667590
Principal investigator 1 Karyopharm Therapeutics Inc. $133.00 06/13/2025 Non-covered Recipient Entity
Weill Cornell Medical College
A Phase 1/2 Open-Label Study of the Safety, Tolerability and Efficacy of the Selective Inhibitor of Nuclear Export (SINE) Compound KPT-8602 in Patients with Relapsed, Refractory Cancer Indications No dispute reported 06/30/2026 1246667592
Principal investigator 1 Karyopharm Therapeutics Inc. $41.23 06/13/2025 Non-covered Recipient Entity
Weill Cornell Medical College
A Phase 1/2 Open-Label Study of the Safety, Tolerability and Efficacy of the Selective Inhibitor of Nuclear Export (SINE) Compound KPT-8602 in Patients with Relapsed, Refractory Cancer Indications No dispute reported 06/30/2026 1246667594
Principal investigator 1 Karyopharm Therapeutics Inc. $170.00 06/13/2025 Non-covered Recipient Entity
Weill Cornell Medical College
A Phase 1/2 Open-Label Study of the Safety, Tolerability and Efficacy of the Selective Inhibitor of Nuclear Export (SINE) Compound KPT-8602 in Patients with Relapsed, Refractory Cancer Indications No dispute reported 06/30/2026 1246667596
Principal investigator 1 Karyopharm Therapeutics Inc. $170.00 06/13/2025 Non-covered Recipient Entity
Weill Cornell Medical College
A Phase 1/2 Open-Label Study of the Safety, Tolerability and Efficacy of the Selective Inhibitor of Nuclear Export (SINE) Compound KPT-8602 in Patients with Relapsed, Refractory Cancer Indications No dispute reported 06/30/2026 1246667598
Principal investigator 1 Karyopharm Therapeutics Inc. $100.00 06/13/2025 Non-covered Recipient Entity
Weill Cornell Medical College
A Phase 1/2 Open-Label Study of the Safety, Tolerability and Efficacy of the Selective Inhibitor of Nuclear Export (SINE) Compound KPT-8602 in Patients with Relapsed, Refractory Cancer Indications No dispute reported 06/30/2026 1246667600
Principal investigator 1 Karyopharm Therapeutics Inc. $170.00 06/13/2025 Non-covered Recipient Entity
Weill Cornell Medical College
A Phase 1/2 Open-Label Study of the Safety, Tolerability and Efficacy of the Selective Inhibitor of Nuclear Export (SINE) Compound KPT-8602 in Patients with Relapsed, Refractory Cancer Indications No dispute reported 06/30/2026 1246667602
Principal investigator 1 Karyopharm Therapeutics Inc. $170.00 06/13/2025 Non-covered Recipient Entity
Weill Cornell Medical College
A Phase 1/2 Open-Label Study of the Safety, Tolerability and Efficacy of the Selective Inhibitor of Nuclear Export (SINE) Compound KPT-8602 in Patients with Relapsed, Refractory Cancer Indications No dispute reported 06/30/2026 1246667604
Principal investigator 1 Karyopharm Therapeutics Inc. $100.00 06/13/2025 Non-covered Recipient Entity
Weill Cornell Medical College
A Phase 1/2 Open-Label Study of the Safety, Tolerability and Efficacy of the Selective Inhibitor of Nuclear Export (SINE) Compound KPT-8602 in Patients with Relapsed, Refractory Cancer Indications No dispute reported 06/30/2026 1246667606
Principal investigator 1 Karyopharm Therapeutics Inc. $170.00 06/13/2025 Non-covered Recipient Entity
Weill Cornell Medical College
A Phase 1/2 Open-Label Study of the Safety, Tolerability and Efficacy of the Selective Inhibitor of Nuclear Export (SINE) Compound KPT-8602 in Patients with Relapsed, Refractory Cancer Indications No dispute reported 06/30/2026 1246667608
Principal investigator 1 Karyopharm Therapeutics Inc. $100.00 06/13/2025 Non-covered Recipient Entity
Weill Cornell Medical College
A Phase 1/2 Open-Label Study of the Safety, Tolerability and Efficacy of the Selective Inhibitor of Nuclear Export (SINE) Compound KPT-8602 in Patients with Relapsed, Refractory Cancer Indications No dispute reported 06/30/2026 1246667610
Principal investigator 1 Karyopharm Therapeutics Inc. $41.23 06/13/2025 Non-covered Recipient Entity
Weill Cornell Medical College
A Phase 1/2 Open-Label Study of the Safety, Tolerability and Efficacy of the Selective Inhibitor of Nuclear Export (SINE) Compound KPT-8602 in Patients with Relapsed, Refractory Cancer Indications No dispute reported 06/30/2026 1246667612
Principal investigator 1 Karyopharm Therapeutics Inc. $170.00 06/13/2025 Non-covered Recipient Entity
Weill Cornell Medical College
A Phase 1/2 Open-Label Study of the Safety, Tolerability and Efficacy of the Selective Inhibitor of Nuclear Export (SINE) Compound KPT-8602 in Patients with Relapsed, Refractory Cancer Indications No dispute reported 06/30/2026 1246667614
Principal investigator 1 Karyopharm Therapeutics Inc. $1,254.15 06/13/2025 Non-covered Recipient Entity
Weill Cornell Medical College
A Phase 1/2 Open-Label Study of the Safety, Tolerability and Efficacy of the Selective Inhibitor of Nuclear Export (SINE) Compound KPT-8602 in Patients with Relapsed, Refractory Cancer Indications No dispute reported 06/30/2026 1246667616
Principal investigator 1 Karyopharm Therapeutics Inc. $133.00 06/13/2025 Non-covered Recipient Entity
Weill Cornell Medical College
A Phase 1/2 Open-Label Study of the Safety, Tolerability and Efficacy of the Selective Inhibitor of Nuclear Export (SINE) Compound KPT-8602 in Patients with Relapsed, Refractory Cancer Indications No dispute reported 06/30/2026 1246667618
Principal investigator 1 Karyopharm Therapeutics Inc. $46.55 06/13/2025 Non-covered Recipient Entity
Weill Cornell Medical College
A Phase 1/2 Open-Label Study of the Safety, Tolerability and Efficacy of the Selective Inhibitor of Nuclear Export (SINE) Compound KPT-8602 in Patients with Relapsed, Refractory Cancer Indications No dispute reported 06/30/2026 1246667620
Principal investigator 1 Karyopharm Therapeutics Inc. $100.00 06/13/2025 Non-covered Recipient Entity
Weill Cornell Medical College
A Phase 1/2 Open-Label Study of the Safety, Tolerability and Efficacy of the Selective Inhibitor of Nuclear Export (SINE) Compound KPT-8602 in Patients with Relapsed, Refractory Cancer Indications No dispute reported 06/30/2026 1246667622
Principal investigator 1 Karyopharm Therapeutics Inc. $607.50 06/13/2025 Non-covered Recipient Entity
Weill Cornell Medical College
A Phase 1/2 Open-Label Study of the Safety, Tolerability and Efficacy of the Selective Inhibitor of Nuclear Export (SINE) Compound KPT-8602 in Patients with Relapsed, Refractory Cancer Indications No dispute reported 06/30/2026 1246667624
Principal investigator 1 Karyopharm Therapeutics Inc. $170.00 06/13/2025 Non-covered Recipient Entity
Weill Cornell Medical College
A Phase 1/2 Open-Label Study of the Safety, Tolerability and Efficacy of the Selective Inhibitor of Nuclear Export (SINE) Compound KPT-8602 in Patients with Relapsed, Refractory Cancer Indications No dispute reported 06/30/2026 1246667626
Principal investigator 1 Karyopharm Therapeutics Inc. $170.00 06/13/2025 Non-covered Recipient Entity
Weill Cornell Medical College
A Phase 1/2 Open-Label Study of the Safety, Tolerability and Efficacy of the Selective Inhibitor of Nuclear Export (SINE) Compound KPT-8602 in Patients with Relapsed, Refractory Cancer Indications No dispute reported 06/30/2026 1246667628
Principal investigator 1 Karyopharm Therapeutics Inc. $311.00 06/13/2025 Non-covered Recipient Entity
Weill Cornell Medical College
A Phase 1/2 Open-Label Study of the Safety, Tolerability and Efficacy of the Selective Inhibitor of Nuclear Export (SINE) Compound KPT-8602 in Patients with Relapsed, Refractory Cancer Indications No dispute reported 06/30/2026 1246667630
Principal investigator 1 Karyopharm Therapeutics Inc. $170.00 06/13/2025 Non-covered Recipient Entity
Weill Cornell Medical College
A Phase 1/2 Open-Label Study of the Safety, Tolerability and Efficacy of the Selective Inhibitor of Nuclear Export (SINE) Compound KPT-8602 in Patients with Relapsed, Refractory Cancer Indications No dispute reported 06/30/2026 1246667632
Principal investigator 1 Karyopharm Therapeutics Inc. $303.00 06/13/2025 Non-covered Recipient Entity
Weill Cornell Medical College
A Phase 1/2 Open-Label Study of the Safety, Tolerability and Efficacy of the Selective Inhibitor of Nuclear Export (SINE) Compound KPT-8602 in Patients with Relapsed, Refractory Cancer Indications No dispute reported 06/30/2026 1246667634
Principal investigator 1 Karyopharm Therapeutics Inc. $41.23 06/13/2025 Non-covered Recipient Entity
Weill Cornell Medical College
A Phase 1/2 Open-Label Study of the Safety, Tolerability and Efficacy of the Selective Inhibitor of Nuclear Export (SINE) Compound KPT-8602 in Patients with Relapsed, Refractory Cancer Indications No dispute reported 06/30/2026 1246667636
Principal investigator 1 Karyopharm Therapeutics Inc. $46.55 06/13/2025 Non-covered Recipient Entity
Weill Cornell Medical College
A Phase 1/2 Open-Label Study of the Safety, Tolerability and Efficacy of the Selective Inhibitor of Nuclear Export (SINE) Compound KPT-8602 in Patients with Relapsed, Refractory Cancer Indications No dispute reported 06/30/2026 1246667638
Principal investigator 1 Karyopharm Therapeutics Inc. $170.00 06/13/2025 Non-covered Recipient Entity
Weill Cornell Medical College
A Phase 1/2 Open-Label Study of the Safety, Tolerability and Efficacy of the Selective Inhibitor of Nuclear Export (SINE) Compound KPT-8602 in Patients with Relapsed, Refractory Cancer Indications No dispute reported 06/30/2026 1246667640
Principal investigator 1 Karyopharm Therapeutics Inc. $300.00 06/13/2025 Non-covered Recipient Entity
Weill Cornell Medical College
A Phase 1/2 Open-Label Study of the Safety, Tolerability and Efficacy of the Selective Inhibitor of Nuclear Export (SINE) Compound KPT-8602 in Patients with Relapsed, Refractory Cancer Indications No dispute reported 06/30/2026 1246667642
Principal investigator 1 Karyopharm Therapeutics Inc. $170.00 06/13/2025 Non-covered Recipient Entity
Weill Cornell Medical College
A Phase 1/2 Open-Label Study of the Safety, Tolerability and Efficacy of the Selective Inhibitor of Nuclear Export (SINE) Compound KPT-8602 in Patients with Relapsed, Refractory Cancer Indications No dispute reported 06/30/2026 1246667644
Principal investigator 1 Karyopharm Therapeutics Inc. $133.00 06/13/2025 Non-covered Recipient Entity
Weill Cornell Medical College
A Phase 1/2 Open-Label Study of the Safety, Tolerability and Efficacy of the Selective Inhibitor of Nuclear Export (SINE) Compound KPT-8602 in Patients with Relapsed, Refractory Cancer Indications No dispute reported 06/30/2026 1246667646
Principal investigator 1 Karyopharm Therapeutics Inc. $100.00 06/13/2025 Non-covered Recipient Entity
Weill Cornell Medical College
A Phase 1/2 Open-Label Study of the Safety, Tolerability and Efficacy of the Selective Inhibitor of Nuclear Export (SINE) Compound KPT-8602 in Patients with Relapsed, Refractory Cancer Indications No dispute reported 06/30/2026 1246667648
Principal investigator 1 Karyopharm Therapeutics Inc. $100.00 06/13/2025 Non-covered Recipient Entity
Weill Cornell Medical College
A Phase 1/2 Open-Label Study of the Safety, Tolerability and Efficacy of the Selective Inhibitor of Nuclear Export (SINE) Compound KPT-8602 in Patients with Relapsed, Refractory Cancer Indications No dispute reported 06/30/2026 1246667650
Principal investigator 1 Karyopharm Therapeutics Inc. $100.00 06/13/2025 Non-covered Recipient Entity
Weill Cornell Medical College
A Phase 1/2 Open-Label Study of the Safety, Tolerability and Efficacy of the Selective Inhibitor of Nuclear Export (SINE) Compound KPT-8602 in Patients with Relapsed, Refractory Cancer Indications No dispute reported 06/30/2026 1246667652
Principal investigator 1 Karyopharm Therapeutics Inc. $320.00 06/13/2025 Non-covered Recipient Entity
Weill Cornell Medical College
A Phase 1/2 Open-Label Study of the Safety, Tolerability and Efficacy of the Selective Inhibitor of Nuclear Export (SINE) Compound KPT-8602 in Patients with Relapsed, Refractory Cancer Indications No dispute reported 06/30/2026 1246667654
Principal investigator 1 Karyopharm Therapeutics Inc. $864.50 06/13/2025 Non-covered Recipient Entity
Weill Cornell Medical College
A Phase 1/2 Open-Label Study of the Safety, Tolerability and Efficacy of the Selective Inhibitor of Nuclear Export (SINE) Compound KPT-8602 in Patients with Relapsed, Refractory Cancer Indications No dispute reported 06/30/2026 1246667656
Principal investigator 1 Karyopharm Therapeutics Inc. $170.00 06/13/2025 Non-covered Recipient Entity
Weill Cornell Medical College
A Phase 1/2 Open-Label Study of the Safety, Tolerability and Efficacy of the Selective Inhibitor of Nuclear Export (SINE) Compound KPT-8602 in Patients with Relapsed, Refractory Cancer Indications No dispute reported 06/30/2026 1246667658
Principal investigator 1 Karyopharm Therapeutics Inc. $41.23 06/13/2025 Non-covered Recipient Entity
Weill Cornell Medical College
A Phase 1/2 Open-Label Study of the Safety, Tolerability and Efficacy of the Selective Inhibitor of Nuclear Export (SINE) Compound KPT-8602 in Patients with Relapsed, Refractory Cancer Indications No dispute reported 06/30/2026 1246667660
Principal investigator 1 Karyopharm Therapeutics Inc. $100.00 06/13/2025 Non-covered Recipient Entity
Weill Cornell Medical College
A Phase 1/2 Open-Label Study of the Safety, Tolerability and Efficacy of the Selective Inhibitor of Nuclear Export (SINE) Compound KPT-8602 in Patients with Relapsed, Refractory Cancer Indications No dispute reported 06/30/2026 1246667662
Principal investigator 1 Karyopharm Therapeutics Inc. $133.00 06/13/2025 Non-covered Recipient Entity
Weill Cornell Medical College
A Phase 1/2 Open-Label Study of the Safety, Tolerability and Efficacy of the Selective Inhibitor of Nuclear Export (SINE) Compound KPT-8602 in Patients with Relapsed, Refractory Cancer Indications No dispute reported 06/30/2026 1246667664
Principal investigator 1 Karyopharm Therapeutics Inc. $46.55 06/13/2025 Non-covered Recipient Entity
Weill Cornell Medical College
A Phase 1/2 Open-Label Study of the Safety, Tolerability and Efficacy of the Selective Inhibitor of Nuclear Export (SINE) Compound KPT-8602 in Patients with Relapsed, Refractory Cancer Indications No dispute reported 06/30/2026 1246667666
Principal investigator 1 Karyopharm Therapeutics Inc. $266.00 06/13/2025 Non-covered Recipient Entity
Weill Cornell Medical College
A Phase 1/2 Open-Label Study of the Safety, Tolerability and Efficacy of the Selective Inhibitor of Nuclear Export (SINE) Compound KPT-8602 in Patients with Relapsed, Refractory Cancer Indications No dispute reported 06/30/2026 1246667668
Principal investigator 1 Karyopharm Therapeutics Inc. $607.50 06/13/2025 Non-covered Recipient Entity
Weill Cornell Medical College
A Phase 1/2 Open-Label Study of the Safety, Tolerability and Efficacy of the Selective Inhibitor of Nuclear Export (SINE) Compound KPT-8602 in Patients with Relapsed, Refractory Cancer Indications No dispute reported 06/30/2026 1246667670
Principal investigator 1 Karyopharm Therapeutics Inc. $133.00 06/13/2025 Non-covered Recipient Entity
Weill Cornell Medical College
A Phase 1/2 Open-Label Study of the Safety, Tolerability and Efficacy of the Selective Inhibitor of Nuclear Export (SINE) Compound KPT-8602 in Patients with Relapsed, Refractory Cancer Indications No dispute reported 06/30/2026 1246667672
Principal investigator 1 Karyopharm Therapeutics Inc. $41.23 06/13/2025 Non-covered Recipient Entity
Weill Cornell Medical College
A Phase 1/2 Open-Label Study of the Safety, Tolerability and Efficacy of the Selective Inhibitor of Nuclear Export (SINE) Compound KPT-8602 in Patients with Relapsed, Refractory Cancer Indications No dispute reported 06/30/2026 1246667674
Principal investigator 1 Karyopharm Therapeutics Inc. $170.00 06/13/2025 Non-covered Recipient Entity
Weill Cornell Medical College
A Phase 1/2 Open-Label Study of the Safety, Tolerability and Efficacy of the Selective Inhibitor of Nuclear Export (SINE) Compound KPT-8602 in Patients with Relapsed, Refractory Cancer Indications No dispute reported 06/30/2026 1246667676
Principal investigator 1 Karyopharm Therapeutics Inc. $300.00 06/13/2025 Non-covered Recipient Entity
Weill Cornell Medical College
A Phase 1/2 Open-Label Study of the Safety, Tolerability and Efficacy of the Selective Inhibitor of Nuclear Export (SINE) Compound KPT-8602 in Patients with Relapsed, Refractory Cancer Indications No dispute reported 06/30/2026 1246667678
Principal investigator 1 Karyopharm Therapeutics Inc. $1,750.00 06/13/2025 Non-covered Recipient Entity
Weill Cornell Medical College
A Phase 1/2 Open-Label Study of the Safety, Tolerability and Efficacy of the Selective Inhibitor of Nuclear Export (SINE) Compound KPT-8602 in Patients with Relapsed, Refractory Cancer Indications No dispute reported 06/30/2026 1246667680
Principal investigator 1 Karyopharm Therapeutics Inc. $170.00 06/13/2025 Non-covered Recipient Entity
Weill Cornell Medical College
A Phase 1/2 Open-Label Study of the Safety, Tolerability and Efficacy of the Selective Inhibitor of Nuclear Export (SINE) Compound KPT-8602 in Patients with Relapsed, Refractory Cancer Indications No dispute reported 06/30/2026 1246667682
Principal investigator 1 Karyopharm Therapeutics Inc. $864.50 06/13/2025 Non-covered Recipient Entity
Weill Cornell Medical College
A Phase 1/2 Open-Label Study of the Safety, Tolerability and Efficacy of the Selective Inhibitor of Nuclear Export (SINE) Compound KPT-8602 in Patients with Relapsed, Refractory Cancer Indications No dispute reported 06/30/2026 1246667684
Principal investigator 1 Karyopharm Therapeutics Inc. $170.00 06/13/2025 Non-covered Recipient Entity
Weill Cornell Medical College
A Phase 1/2 Open-Label Study of the Safety, Tolerability and Efficacy of the Selective Inhibitor of Nuclear Export (SINE) Compound KPT-8602 in Patients with Relapsed, Refractory Cancer Indications No dispute reported 06/30/2026 1246667686
Principal investigator 1 Karyopharm Therapeutics Inc. $46.55 06/13/2025 Non-covered Recipient Entity
Weill Cornell Medical College
A Phase 1/2 Open-Label Study of the Safety, Tolerability and Efficacy of the Selective Inhibitor of Nuclear Export (SINE) Compound KPT-8602 in Patients with Relapsed, Refractory Cancer Indications No dispute reported 06/30/2026 1246667688
Principal investigator 1 Karyopharm Therapeutics Inc. $170.00 06/13/2025 Non-covered Recipient Entity
Weill Cornell Medical College
A Phase 1/2 Open-Label Study of the Safety, Tolerability and Efficacy of the Selective Inhibitor of Nuclear Export (SINE) Compound KPT-8602 in Patients with Relapsed, Refractory Cancer Indications No dispute reported 06/30/2026 1246667690
Principal investigator 1 Karyopharm Therapeutics Inc. $170.00 06/13/2025 Non-covered Recipient Entity
Weill Cornell Medical College
A Phase 1/2 Open-Label Study of the Safety, Tolerability and Efficacy of the Selective Inhibitor of Nuclear Export (SINE) Compound KPT-8602 in Patients with Relapsed, Refractory Cancer Indications No dispute reported 06/30/2026 1246667692
Principal investigator 1 Karyopharm Therapeutics Inc. $41.23 06/13/2025 Non-covered Recipient Entity
Weill Cornell Medical College
A Phase 1/2 Open-Label Study of the Safety, Tolerability and Efficacy of the Selective Inhibitor of Nuclear Export (SINE) Compound KPT-8602 in Patients with Relapsed, Refractory Cancer Indications No dispute reported 06/30/2026 1246667694
Principal investigator 1 Karyopharm Therapeutics Inc. $42.56 06/13/2025 Non-covered Recipient Entity
Weill Cornell Medical College
A Phase 1/2 Open-Label Study of the Safety, Tolerability and Efficacy of the Selective Inhibitor of Nuclear Export (SINE) Compound KPT-8602 in Patients with Relapsed, Refractory Cancer Indications No dispute reported 06/30/2026 1246667696
Principal investigator 1 Karyopharm Therapeutics Inc. $170.00 06/13/2025 Non-covered Recipient Entity
Weill Cornell Medical College
A Phase 1/2 Open-Label Study of the Safety, Tolerability and Efficacy of the Selective Inhibitor of Nuclear Export (SINE) Compound KPT-8602 in Patients with Relapsed, Refractory Cancer Indications No dispute reported 06/30/2026 1246667698
Principal investigator 1 Karyopharm Therapeutics Inc. $41.23 06/13/2025 Non-covered Recipient Entity
Weill Cornell Medical College
A Phase 1/2 Open-Label Study of the Safety, Tolerability and Efficacy of the Selective Inhibitor of Nuclear Export (SINE) Compound KPT-8602 in Patients with Relapsed, Refractory Cancer Indications No dispute reported 06/30/2026 1246667700
Principal investigator 1 Karyopharm Therapeutics Inc. $133.00 06/13/2025 Non-covered Recipient Entity
Weill Cornell Medical College
A Phase 1/2 Open-Label Study of the Safety, Tolerability and Efficacy of the Selective Inhibitor of Nuclear Export (SINE) Compound KPT-8602 in Patients with Relapsed, Refractory Cancer Indications No dispute reported 06/30/2026 1246667702
Principal investigator 1 Karyopharm Therapeutics Inc. $488.00 06/13/2025 Non-covered Recipient Entity
Weill Cornell Medical College
A Phase 1/2 Open-Label Study of the Safety, Tolerability and Efficacy of the Selective Inhibitor of Nuclear Export (SINE) Compound KPT-8602 in Patients with Relapsed, Refractory Cancer Indications No dispute reported 06/30/2026 1246667704
Principal investigator 1 Karyopharm Therapeutics Inc. $133.00 06/13/2025 Non-covered Recipient Entity
Weill Cornell Medical College
A Phase 1/2 Open-Label Study of the Safety, Tolerability and Efficacy of the Selective Inhibitor of Nuclear Export (SINE) Compound KPT-8602 in Patients with Relapsed, Refractory Cancer Indications No dispute reported 06/30/2026 1246667706
Principal investigator 1 Karyopharm Therapeutics Inc. $100.00 06/13/2025 Non-covered Recipient Entity
Weill Cornell Medical College
A Phase 1/2 Open-Label Study of the Safety, Tolerability and Efficacy of the Selective Inhibitor of Nuclear Export (SINE) Compound KPT-8602 in Patients with Relapsed, Refractory Cancer Indications No dispute reported 06/30/2026 1246667708
Principal investigator 1 Karyopharm Therapeutics Inc. $170.00 06/13/2025 Non-covered Recipient Entity
Weill Cornell Medical College
A Phase 1/2 Open-Label Study of the Safety, Tolerability and Efficacy of the Selective Inhibitor of Nuclear Export (SINE) Compound KPT-8602 in Patients with Relapsed, Refractory Cancer Indications No dispute reported 06/30/2026 1246667710
Principal investigator 1 Karyopharm Therapeutics Inc. $266.00 06/13/2025 Non-covered Recipient Entity
Weill Cornell Medical College
A Phase 1/2 Open-Label Study of the Safety, Tolerability and Efficacy of the Selective Inhibitor of Nuclear Export (SINE) Compound KPT-8602 in Patients with Relapsed, Refractory Cancer Indications No dispute reported 06/30/2026 1246667712
Principal investigator 1 Karyopharm Therapeutics Inc. $928.80 06/13/2025 Non-covered Recipient Entity
Weill Cornell Medical College
A Phase 1/2 Open-Label Study of the Safety, Tolerability and Efficacy of the Selective Inhibitor of Nuclear Export (SINE) Compound KPT-8602 in Patients with Relapsed, Refractory Cancer Indications No dispute reported 06/30/2026 1246667714
Principal investigator 1 Karyopharm Therapeutics Inc. $100.00 06/13/2025 Non-covered Recipient Entity
Weill Cornell Medical College
A Phase 1/2 Open-Label Study of the Safety, Tolerability and Efficacy of the Selective Inhibitor of Nuclear Export (SINE) Compound KPT-8602 in Patients with Relapsed, Refractory Cancer Indications No dispute reported 06/30/2026 1246667716
Principal investigator 1 Karyopharm Therapeutics Inc. $100.00 06/13/2025 Non-covered Recipient Entity
Weill Cornell Medical College
A Phase 1/2 Open-Label Study of the Safety, Tolerability and Efficacy of the Selective Inhibitor of Nuclear Export (SINE) Compound KPT-8602 in Patients with Relapsed, Refractory Cancer Indications No dispute reported 06/30/2026 1246667718
Principal investigator 1 Karyopharm Therapeutics Inc. $100.00 06/13/2025 Non-covered Recipient Entity
Weill Cornell Medical College
A Phase 1/2 Open-Label Study of the Safety, Tolerability and Efficacy of the Selective Inhibitor of Nuclear Export (SINE) Compound KPT-8602 in Patients with Relapsed, Refractory Cancer Indications No dispute reported 06/30/2026 1246667720
Principal investigator 1 Karyopharm Therapeutics Inc. $100.00 06/13/2025 Non-covered Recipient Entity
Weill Cornell Medical College
A Phase 1/2 Open-Label Study of the Safety, Tolerability and Efficacy of the Selective Inhibitor of Nuclear Export (SINE) Compound KPT-8602 in Patients with Relapsed, Refractory Cancer Indications No dispute reported 06/30/2026 1246667722
Principal investigator 1 Karyopharm Therapeutics Inc. $170.00 06/13/2025 Non-covered Recipient Entity
Weill Cornell Medical College
A Phase 1/2 Open-Label Study of the Safety, Tolerability and Efficacy of the Selective Inhibitor of Nuclear Export (SINE) Compound KPT-8602 in Patients with Relapsed, Refractory Cancer Indications No dispute reported 06/30/2026 1246667724
Principal investigator 1 Karyopharm Therapeutics Inc. $170.00 06/13/2025 Non-covered Recipient Entity
Weill Cornell Medical College
A Phase 1/2 Open-Label Study of the Safety, Tolerability and Efficacy of the Selective Inhibitor of Nuclear Export (SINE) Compound KPT-8602 in Patients with Relapsed, Refractory Cancer Indications No dispute reported 06/30/2026 1246667726
Principal investigator 1 Karyopharm Therapeutics Inc. $170.00 06/13/2025 Non-covered Recipient Entity
Weill Cornell Medical College
A Phase 1/2 Open-Label Study of the Safety, Tolerability and Efficacy of the Selective Inhibitor of Nuclear Export (SINE) Compound KPT-8602 in Patients with Relapsed, Refractory Cancer Indications No dispute reported 06/30/2026 1246667728
Principal investigator 1 Karyopharm Therapeutics Inc. $170.00 06/13/2025 Non-covered Recipient Entity
Weill Cornell Medical College
A Phase 1/2 Open-Label Study of the Safety, Tolerability and Efficacy of the Selective Inhibitor of Nuclear Export (SINE) Compound KPT-8602 in Patients with Relapsed, Refractory Cancer Indications No dispute reported 06/30/2026 1246667730
Principal investigator 1 Karyopharm Therapeutics Inc. $133.00 06/13/2025 Non-covered Recipient Entity
Weill Cornell Medical College
A Phase 1/2 Open-Label Study of the Safety, Tolerability and Efficacy of the Selective Inhibitor of Nuclear Export (SINE) Compound KPT-8602 in Patients with Relapsed, Refractory Cancer Indications No dispute reported 06/30/2026 1246667732
Principal investigator 1 Karyopharm Therapeutics Inc. $133.00 06/13/2025 Non-covered Recipient Entity
Weill Cornell Medical College
A Phase 1/2 Open-Label Study of the Safety, Tolerability and Efficacy of the Selective Inhibitor of Nuclear Export (SINE) Compound KPT-8602 in Patients with Relapsed, Refractory Cancer Indications No dispute reported 06/30/2026 1246667734
Principal investigator 1 Karyopharm Therapeutics Inc. $266.00 06/13/2025 Non-covered Recipient Entity
Weill Cornell Medical College
A Phase 1/2 Open-Label Study of the Safety, Tolerability and Efficacy of the Selective Inhibitor of Nuclear Export (SINE) Compound KPT-8602 in Patients with Relapsed, Refractory Cancer Indications No dispute reported 06/30/2026 1246667736
Principal investigator 1 Karyopharm Therapeutics Inc. $293.00 06/13/2025 Non-covered Recipient Entity
Weill Cornell Medical College
A Phase 1/2 Open-Label Study of the Safety, Tolerability and Efficacy of the Selective Inhibitor of Nuclear Export (SINE) Compound KPT-8602 in Patients with Relapsed, Refractory Cancer Indications No dispute reported 06/30/2026 1246667738
Principal investigator 1 Karyopharm Therapeutics Inc. $100.00 06/13/2025 Non-covered Recipient Entity
Weill Cornell Medical College
A Phase 1/2 Open-Label Study of the Safety, Tolerability and Efficacy of the Selective Inhibitor of Nuclear Export (SINE) Compound KPT-8602 in Patients with Relapsed, Refractory Cancer Indications No dispute reported 06/30/2026 1246667740
Principal investigator 1 Karyopharm Therapeutics Inc. $100.00 06/13/2025 Non-covered Recipient Entity
Weill Cornell Medical College
A Phase 1/2 Open-Label Study of the Safety, Tolerability and Efficacy of the Selective Inhibitor of Nuclear Export (SINE) Compound KPT-8602 in Patients with Relapsed, Refractory Cancer Indications No dispute reported 06/30/2026 1246667742
Principal investigator 1 Karyopharm Therapeutics Inc. $266.00 06/13/2025 Non-covered Recipient Entity
Weill Cornell Medical College
A Phase 1/2 Open-Label Study of the Safety, Tolerability and Efficacy of the Selective Inhibitor of Nuclear Export (SINE) Compound KPT-8602 in Patients with Relapsed, Refractory Cancer Indications No dispute reported 06/30/2026 1246667744
Principal investigator 1 Karyopharm Therapeutics Inc. $42.56 06/13/2025 Non-covered Recipient Entity
Weill Cornell Medical College
A Phase 1/2 Open-Label Study of the Safety, Tolerability and Efficacy of the Selective Inhibitor of Nuclear Export (SINE) Compound KPT-8602 in Patients with Relapsed, Refractory Cancer Indications No dispute reported 06/30/2026 1246667746
Principal investigator 1 Karyopharm Therapeutics Inc. $320.00 06/13/2025 Non-covered Recipient Entity
Weill Cornell Medical College
A Phase 1/2 Open-Label Study of the Safety, Tolerability and Efficacy of the Selective Inhibitor of Nuclear Export (SINE) Compound KPT-8602 in Patients with Relapsed, Refractory Cancer Indications No dispute reported 06/30/2026 1246667748
Principal investigator 1 Karyopharm Therapeutics Inc. $100.00 06/13/2025 Non-covered Recipient Entity
Weill Cornell Medical College
A Phase 1/2 Open-Label Study of the Safety, Tolerability and Efficacy of the Selective Inhibitor of Nuclear Export (SINE) Compound KPT-8602 in Patients with Relapsed, Refractory Cancer Indications No dispute reported 06/30/2026 1246667750
Principal investigator 1 Karyopharm Therapeutics Inc. $283.00 06/13/2025 Non-covered Recipient Entity
Weill Cornell Medical College
A Phase 1/2 Open-Label Study of the Safety, Tolerability and Efficacy of the Selective Inhibitor of Nuclear Export (SINE) Compound KPT-8602 in Patients with Relapsed, Refractory Cancer Indications No dispute reported 06/30/2026 1246667752
Principal investigator 1 Karyopharm Therapeutics Inc. $170.00 06/13/2025 Non-covered Recipient Entity
Weill Cornell Medical College
A Phase 1/2 Open-Label Study of the Safety, Tolerability and Efficacy of the Selective Inhibitor of Nuclear Export (SINE) Compound KPT-8602 in Patients with Relapsed, Refractory Cancer Indications No dispute reported 06/30/2026 1246667754
Principal investigator 1 Karyopharm Therapeutics Inc. $266.00 06/13/2025 Non-covered Recipient Entity
Weill Cornell Medical College
A Phase 1/2 Open-Label Study of the Safety, Tolerability and Efficacy of the Selective Inhibitor of Nuclear Export (SINE) Compound KPT-8602 in Patients with Relapsed, Refractory Cancer Indications No dispute reported 06/30/2026 1246667756
Principal investigator 1 Karyopharm Therapeutics Inc. $170.00 06/13/2025 Non-covered Recipient Entity
Weill Cornell Medical College
A Phase 1/2 Open-Label Study of the Safety, Tolerability and Efficacy of the Selective Inhibitor of Nuclear Export (SINE) Compound KPT-8602 in Patients with Relapsed, Refractory Cancer Indications No dispute reported 06/30/2026 1246667758
Principal investigator 1 Karyopharm Therapeutics Inc. $100.00 06/13/2025 Non-covered Recipient Entity
Weill Cornell Medical College
A Phase 1/2 Open-Label Study of the Safety, Tolerability and Efficacy of the Selective Inhibitor of Nuclear Export (SINE) Compound KPT-8602 in Patients with Relapsed, Refractory Cancer Indications No dispute reported 06/30/2026 1246667760
Principal investigator 1 Karyopharm Therapeutics Inc. $170.00 06/13/2025 Non-covered Recipient Entity
Weill Cornell Medical College
A Phase 1/2 Open-Label Study of the Safety, Tolerability and Efficacy of the Selective Inhibitor of Nuclear Export (SINE) Compound KPT-8602 in Patients with Relapsed, Refractory Cancer Indications No dispute reported 06/30/2026 1246667762
Principal investigator 1 Karyopharm Therapeutics Inc. $41.23 06/13/2025 Non-covered Recipient Entity
Weill Cornell Medical College
A Phase 1/2 Open-Label Study of the Safety, Tolerability and Efficacy of the Selective Inhibitor of Nuclear Export (SINE) Compound KPT-8602 in Patients with Relapsed, Refractory Cancer Indications No dispute reported 06/30/2026 1246667764
Principal investigator 1 Karyopharm Therapeutics Inc. $42.56 06/13/2025 Non-covered Recipient Entity
Weill Cornell Medical College
A Phase 1/2 Open-Label Study of the Safety, Tolerability and Efficacy of the Selective Inhibitor of Nuclear Export (SINE) Compound KPT-8602 in Patients with Relapsed, Refractory Cancer Indications No dispute reported 06/30/2026 1246667766
Principal investigator 1 Karyopharm Therapeutics Inc. $170.00 06/13/2025 Non-covered Recipient Entity
Weill Cornell Medical College
A Phase 1/2 Open-Label Study of the Safety, Tolerability and Efficacy of the Selective Inhibitor of Nuclear Export (SINE) Compound KPT-8602 in Patients with Relapsed, Refractory Cancer Indications No dispute reported 06/30/2026 1246667768
Principal investigator 1 Karyopharm Therapeutics Inc. $46.55 06/13/2025 Non-covered Recipient Entity
Weill Cornell Medical College
A Phase 1/2 Open-Label Study of the Safety, Tolerability and Efficacy of the Selective Inhibitor of Nuclear Export (SINE) Compound KPT-8602 in Patients with Relapsed, Refractory Cancer Indications No dispute reported 06/30/2026 1246667770
Principal investigator 1 SERVIER PHARMACEUTICALS LLC $57,601.16 06/05/2025 Non-covered Recipient Entity
WEILL CORNELL MEDICINE
A PHASE I, MULTICENTER, OPEN-LABEL, DOSE-ESCALATION AND EXPANSION, SAFETY, PHARMACOKINETIC, PHARMACODYNAMIC, AND CLINICAL ACTIVITY STUDY OF ORALLY ADMINISTERED AG-120 IN SUBJECTS WITH ADVANCED HEMATOLOGIC MALIGNANCIES WITH AN IDH1 MUTATION No dispute reported 06/30/2026 1235978157
Principal investigator 1 SERVIER PHARMACEUTICALS LLC $57,601.16 06/05/2025 Non-covered Recipient Entity
WEILL CORNELL MEDICINE
A PHASE I, MULTICENTER, OPEN-LABEL, DOSE-ESCALATION AND EXPANSION, SAFETY, PHARMACOKINETIC, PHARMACODYNAMIC, AND CLINICAL ACTIVITY STUDY OF ORALLY ADMINISTERED AG-120 IN SUBJECTS WITH ADVANCED HEMATOLOGIC MALIGNANCIES WITH AN IDH1 MUTATION No dispute reported 06/30/2026 1235978159
Principal investigator 1 TAIHO ONCOLOGY, INC. $233,699.13 06/04/2025 Non-covered Recipient Entity
Weill Medical College Of Cornell University
ASTX727-07 No dispute reported 06/30/2026 1211415509
Principal investigator 1 Novartis Pharmaceuticals Corporation $31,022.50 06/03/2025 Non-covered Recipient Entity
WEILL CORNELL MEDICAL COLLEGE
A Phase II Multi-center, Single Arm, Safety and Efficacy Study of MBG453 in Combination With Azacitidine and Venetoclax for the Treatment of Acute Myeloid Leukemia (AML) in Adult Patients Unfit for Chemotherapy No dispute reported 06/30/2026 1190303979
Principal investigator 1 ABBVIE INC. $338.85 06/02/2025 Non-covered Recipient Entity
WEILL MEDICAL COLLEGE OF CORNELL UNIVERSITY
Study to Evaluate Adverse Events and Movement of Intravenously (IV) Infused ABBV-787 in Adult Participants With Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) No dispute reported 06/30/2026 1202487191
Principal investigator 1 ABBVIE INC. $4,500.00 06/02/2025 Non-covered Recipient Entity
WEILL MEDICAL COLLEGE OF CORNELL UNIVERSITY
Study to Evaluate Adverse Events and Movement of Intravenously (IV) Infused ABBV-787 in Adult Participants With Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) No dispute reported 06/30/2026 1202487213
Principal investigator 1 ABBVIE INC. $338.85 06/02/2025 Non-covered Recipient Entity
WEILL MEDICAL COLLEGE OF CORNELL UNIVERSITY
Study to Evaluate Adverse Events and Movement of Intravenously (IV) Infused ABBV-787 in Adult Participants With Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) No dispute reported 06/30/2026 1202487215
Principal investigator 1 ABBVIE INC. $1,701.00 06/02/2025 Non-covered Recipient Entity
WEILL MEDICAL COLLEGE OF CORNELL UNIVERSITY
Study to Evaluate Adverse Events and Movement of Intravenously (IV) Infused ABBV-787 in Adult Participants With Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) No dispute reported 06/30/2026 1202487217
Principal investigator 1 ABBVIE INC. $4,000.00 06/02/2025 Non-covered Recipient Entity
WEILL MEDICAL COLLEGE OF CORNELL UNIVERSITY
Study to Evaluate Adverse Events and Movement of Intravenously (IV) Infused ABBV-787 in Adult Participants With Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) No dispute reported 06/30/2026 1202487225
Principal investigator 1 ABBVIE INC. $1,000.00 06/02/2025 Non-covered Recipient Entity
WEILL MEDICAL COLLEGE OF CORNELL UNIVERSITY
Study to Evaluate Adverse Events and Movement of Intravenously (IV) Infused ABBV-787 in Adult Participants With Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) No dispute reported 06/30/2026 1202487227
Principal investigator 1 ABBVIE INC. $15,000.00 06/02/2025 Non-covered Recipient Entity
WEILL MEDICAL COLLEGE OF CORNELL UNIVERSITY
Study to Evaluate Adverse Events and Movement of Intravenously (IV) Infused ABBV-787 in Adult Participants With Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) No dispute reported 06/30/2026 1202487229
Principal investigator 1 ABBVIE INC. $15,000.00 06/02/2025 Non-covered Recipient Entity
WEILL MEDICAL COLLEGE OF CORNELL UNIVERSITY
Study to Evaluate Adverse Events and Movement of Intravenously (IV) Infused ABBV-787 in Adult Participants With Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) No dispute reported 06/30/2026 1202487231
Principal investigator 1 ABBVIE INC. $4,000.00 06/02/2025 Non-covered Recipient Entity
WEILL MEDICAL COLLEGE OF CORNELL UNIVERSITY
Study to Evaluate Adverse Events and Movement of Intravenously (IV) Infused ABBV-787 in Adult Participants With Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) No dispute reported 06/30/2026 1202487233
Principal investigator 1 ABBVIE INC. $500.00 06/02/2025 Non-covered Recipient Entity
WEILL MEDICAL COLLEGE OF CORNELL UNIVERSITY
Study to Evaluate Adverse Events and Movement of Intravenously (IV) Infused ABBV-787 in Adult Participants With Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) No dispute reported 06/30/2026 1202487239
Principal investigator 1 ABBVIE INC. $866.25 04/28/2025 Non-covered Recipient Entity
WEILL MEDICAL COLLEGE OF CORNELL UNIVERSITY
Study to Evaluate Adverse Events and Movement of Intravenously (IV) Infused ABBV-787 in Adult Participants With Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) No dispute reported 06/30/2026 1202479745
Principal investigator 1 ABBVIE INC. $1,182.60 03/31/2025 Non-covered Recipient Entity
WEILL MEDICAL COLLEGE OF CORNELL UNIVERSITY
Study to Evaluate Adverse Events and Movement of Intravenously (IV) Infused ABBV-787 in Adult Participants With Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) No dispute reported 06/30/2026 1202467615
Principal investigator 1 ABBVIE INC. $4,685.85 02/05/2025 Non-covered Recipient Entity
WEILL MEDICAL COLLEGE OF CORNELL UNIVERSITY
Study to Evaluate Adverse Events and Movement of Intravenously (IV) Infused ABBV-787 in Adult Participants With Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) No dispute reported 06/30/2026 1202446545
Principal investigator 1 ABBVIE INC. $1,522.80 02/05/2025 Non-covered Recipient Entity
WEILL MEDICAL COLLEGE OF CORNELL UNIVERSITY
Study to Evaluate Adverse Events and Movement of Intravenously (IV) Infused ABBV-787 in Adult Participants With Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) No dispute reported 06/30/2026 1202446549
Principal investigator 1 ABBVIE INC. $8,484.75 02/05/2025 Non-covered Recipient Entity
WEILL MEDICAL COLLEGE OF CORNELL UNIVERSITY
Study to Evaluate Adverse Events and Movement of Intravenously (IV) Infused ABBV-787 in Adult Participants With Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) No dispute reported 06/30/2026 1202446552
Principal investigator 1 ABBVIE INC. $4,951.80 02/05/2025 Non-covered Recipient Entity
WEILL MEDICAL COLLEGE OF CORNELL UNIVERSITY
Study to Evaluate Adverse Events and Movement of Intravenously (IV) Infused ABBV-787 in Adult Participants With Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) No dispute reported 06/30/2026 1202446556
Principal investigator 1 ABBVIE INC. $3,564.00 02/05/2025 Non-covered Recipient Entity
WEILL MEDICAL COLLEGE OF CORNELL UNIVERSITY
Study to Evaluate Adverse Events and Movement of Intravenously (IV) Infused ABBV-787 in Adult Participants With Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) No dispute reported 06/30/2026 1202446560
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $40,143.00 02/04/2025 Non-covered Recipient Entity
Weill Medical College Of Cornell University
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Compare Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care Versus Best Supportive Care as Maintenance Therapy in Subjects w/Acute Myeloid Leukemia in Complete Remission No dispute reported 06/30/2026 1235991734
Principal investigator 1 Novartis Pharmaceuticals Corporation $180.00 01/01/2025 Non-covered Recipient Entity
WEILL CORNELL MEDICAL CENTER
A Phase II Multi-center, Single Arm, Safety and Efficacy Study of MBG453 in Combination With Azacitidine and Venetoclax for the Treatment of Acute Myeloid Leukemia (AML) in Adult Patients Unfit for Chemotherapy No dispute reported 06/30/2026 1190305585